CN104936951A - Novel benzimidazole derivatives as kinase inhibitors - Google Patents

Novel benzimidazole derivatives as kinase inhibitors Download PDF

Info

Publication number
CN104936951A
CN104936951A CN201380067040.1A CN201380067040A CN104936951A CN 104936951 A CN104936951 A CN 104936951A CN 201380067040 A CN201380067040 A CN 201380067040A CN 104936951 A CN104936951 A CN 104936951A
Authority
CN
China
Prior art keywords
alkyl
yuan
heterocycle
compound
substituting group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380067040.1A
Other languages
Chinese (zh)
Other versions
CN104936951B (en
Inventor
沃伊切赫·察尔迪邦
克日什托夫·布若佐卡
米夏尔·加莱佐夫斯基
雷娜塔·温达克
马里乌什·米利克
玛格达莱娜·扎瓦兹卡
帕维尔·古济克
埃韦利纳·温恰
玛尔塔·普罗科普
卡塔日娜·维克利克
亚历山德拉·萨比尼亚日
维斯瓦夫·马雷克·乔洛迪
雷蒙德·霍尔瓦特
托马斯·日姆斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruiwu Treatment Co ltd
Original Assignee
Selvita Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sp zoo filed Critical Selvita Sp zoo
Publication of CN104936951A publication Critical patent/CN104936951A/en
Application granted granted Critical
Publication of CN104936951B publication Critical patent/CN104936951B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3-and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.

Description

As the new benzimidazole derivatives of kinase inhibitor
Technical field
The present invention relates to new benzimidazole derivatives and pharmacologically acceptable salt thereof.Such derivative is effective inhibitor of some serine/threonine and Tyrosylprotein kinase (and particularly PIM1-3 kinases and DYRK1A kinases).The invention still further relates to the pharmaceutical composition comprising such derivative, wherein said pharmaceutical composition can be used for treatment PIM1-3 kinases and DYRK1A kinase-associated conditions, such as cancer (particularly leukemia, lymphoma and solid tumor), autoimmune disease, inflammatory diseases and neurodegenerative disease especially.
Background technology
Kinases adds to other protein the enzyme that phosphate group (this process is called phosphorylation) modifies described protein by chemical mode.The phosphorylation of target protein not only causes the functional change of its activity, but also can modify and the association of other protein, transport and Subcellular Localization.According to estimates, have in all protein up to 30% can modify by kinases.Therefore, kinases is the key regulator of most cells approach (especially relate to signal transduction those).Kinases is the most interesting current and one of drug targets the most extensively studied.In the new kinases target that current found being used for the treatment of property suppresses, one of emerging molecular target that PIM kinases is the most interesting beyond doubt.The serine-threonine kinase of PIM family is made up of protein PIM-1, PIM-2 and PIM-3 of three kinds of very high homology, they play a significant role in Cellular Signaling Transduction Mediated, and in the approach relating to cell survival, inflammation, cell movement and stress response, there is contribution and (please refer to recent summary Blanco-Aparicio Biochem Pharmacol.2012 October 5, Nawijn, Nat RevCancer.2011 January; 11 (1): 23-34).
PIM-1 is participated in the molecular mechanism of cancerous transformation and cancer generation, the multiple processes regulated and controled by PIM-1 kinases can be pointed out, as the co-activating of irritation cell cycle progression, mTOR approach, Apoptosis inhibitor, the transcribing co-activating, promote resistance and cell migration and transfer of c-Myc.In kinds cancer type, report PIM kinases process LAN, scope from Hematopoietic Malignancies (such as, disseminated B-cell lymphoma, chronic lymphocytic leukemia and acute myelogene leukemia) to solid tumor (such as, prostate cancer and carcinoma of the pancreas).In PIM-1 gene, obtain sudden change may be participate in follicular lymphoma (follicular lymphoma, and chronic bone-marrow-derived lymphocyte leukemia (B-chronic lymphocytic leukemia FL), B-CLL) histology is converted into dispersivity large B cell lymphoid tumor (diffuse large B-cell lymphoma, DLBCL) one of molecular mechanism (Rossi etc., Heamatologica, the 2006,91st volume, 10th phase, 1405-9 page).Also at the non-Hodgkin lymphoma (Gaidano etc. that AIDS is relevant, Blood, 2003, 102nd volume, 5th phase, 1833 to 1841 page), the B cell NHL patient (Libra etc. of HCV infection, J.Pathology, 2005, 206th volume, 1st phase, 87 to 91 page), primary central nervous system lymphoma (primary central nervous system lymphoma, PCNSL) (Montesinos-Rongen etc., Blood, on March 1st, 2004, 103rd volume, 5th phase, 1869 to 1875 page), tie outer DLBCL case and primary cutaneous marginal zone B-cell lymphoma (primary cutaneous marginal zone B-cell lymphoma, PCMZL) (Deutsch etc., J Invest Dermatol.2009 February, 129 (2): 476-9, Deutsch etc., Blood, on April 15th, 2007,109th volume, 8th phase, 3500 to 3504 page), Primary Mediastinal large B cell lymphoid tumor (primary mediastinal large B-cell lymphoma, PMLBCL) (Martelli etc., Crit Rev Oncol Hematol.2008 December, 68 (3): 256-63.) sudden change of PIM-1 gene is detected in case.In the B cell that Epstein-Barr virus (EpsteinBarr virus) infects, PIM-1 kinases raises, and wherein PIM-1 kinases strengthens the transcriptional activity of EBNA2 albumen, and this growth conversion for infected B cell and immortalization are required.The kinase whose this mechanism of action of PIM-1 can make the B cell of immortalization tend to occur vicious transformation (Rainio etc., Virology.2005 March 15; 333 (2): 201-6).
PIM-1 seems also in the generation of acute myeloid leukaemia (acute myeloid leukemia, AML), to play key effect.Many sections of reports point out the effect of PIM-1 kinases in downstream FLT3 (Fms sample Tyrosylprotein kinase 3) kinase signal transduction.Inner tandem sequence repeats (internal tandem duplication, the ITD) sudden change of the composing type activation of receptor tyrosine kinase FLT3 plays a significant role in leukemia occurs, and its existence is relevant with the poor prognosis in AML.Composing type FLT3 intracellular signaling makes the PIM-1 level in leukemia cell raise, and the nearly spanning domain of FLT3 is key structure territory required for this rise (Kim etc., Blood.2005 February 15; 105 (4): 1759-67; Vu etc., Biochem Biophys Res Commun.2009 June 5; 383 (3): 308-13).Interestingly, the conduction of this downstream signal seems to have nothing to do with STAT5, Akt and MAPK intracellular signaling.The kinase whose rise of PIM-1 is conducive to propagation caused by FLT3 intracellular signaling and anti-apoptotic approach, and the main Anti-G value mechanism dependent Bad phosphorylation that is PIM-1 (Kim etc., Br J Haematol.2006 September; 134 (5): 500-9).Similar with FLT3, PIM-1 kinases also raise by Bcr-Abl fusion rotein, this is the major cause of chronic myelogenous leukemia.The Bcr/Abl kinases of SH3/SH2 mediation and the interaction of Hck kinases (hematopoietic cell kinases, hematopoietic cell kinase) cause the activation of Hck and STAT5B to the phosphorylation of key Tyr699 residue.The STAT5B of activation stimulates downstream effect thing (such as, PIM-1 kinases and A1 albumen) expression, its be Bcr/Abl in the vitro conversion that mediates and body leukemia there is required key factor (Klejman etc., EMBO be on November 1, in J.2002; 21 (21): 5766-74; Nieborowska-Skorska etc., Blood.2002 June 15; 99 (12): 4531-9).And suppress the conversion that PIM-1 seems to be not enough to overcome in the cancer cells of Bcr/Abl mediation, the exquisiteness research display of Adam etc., PIM-1 and PIM-2 plays the effect of redundancy at this, simultaneously these two kinds of kinases of target can obtain infusive treatment replacement scheme to overcome resistance to small molecule tyrosine kinase inhibitors (Nosaka and Kitamura, Exp Hematol.2002 July; 30 (7): 697-702; Adam etc., Cancer Res.2006 April 1; 66 (7): 3828-35).In the past few years, have extensively studied the kinase whose participation situation of PIM-1 in prostate cancer generation, and provide the ultimate principle of Multi-instance and the treatment indication with clinical importance.Calendar year 2001, in array screening, show PIM-1 express and be associated with Disease Clinical result, and proposed that it is better mark (Dhanasekaran etc., Nature.2001 August 23 of the standard diagnostic being better than PSA level in serum; 412 (6849): 822-6).This results in by other groups further confirmation (Cibull etc., J Clin Pathol.2006 March of research of carrying out; 59 (3): 285-8; Xu etc., J Surg Oncol.2005 December 15; 92 (4): 326-30; Thompson etc., Lab Invest.2003 September; 83 (9): 1301-9.; Valdman etc., Prostate.2004 September 1; 60 (4): 367-71).In Human Prostate Cancer Cells, the process LAN of PIM-1 carrys out induced gene group unstable by destroying mitotic spindle check position, centriole amplification, chromosomal errors gathering and polyploidy.When PIM-1 kinases is in immortalization, nononcogenic people's cell during process LAN, these cells become (Roh etc., PLoS One.2008 July 2 of tumorigenicity; 3 (7): e2572; Roh etc., Cancer Res.2003 December 1; 63 (23): 8079-84).The very interesting discovery of Zemskova and colleague is supported in prostate cancer therapy and uses PIM-1 kinase inhibitor extraly.Surprisingly, the transcriptional upregulation of prostate cancer cell induction STAT3 phosphorylation and PIM-1 gene is processed with docetaxel (standard care).As struck as shown in low and inhibitors experiment, after docetaxel process, the kinase whose expression of PIM-1 is most important for the survival of these cells.This Data support further test new small molecule kinase inhibitor (Zemskova etc., J BiolChem.2008 July 25 in the combination therapy of docetaxel resistant patients; 283 (30): 20635-44).In the extensive research of Beier etc., the immunohistochemical experiment display that cell carries out, compared with nonneoplastic tissue, PIM-1 protein overexpression is had in aggressive squamous cell carcinoma of the head and neck (head and neck squamous cell carcinoma, HNSCC) 98% (41/42).Use primary tumor and transfer biopsy samples to repeat this research, display PIM-1 expresses and be close to significant dependency between histologic tumor, has highlighted the effect of PIM-1 in HNSCC occurs (Beier etc., Int J Oncol.2007 June; 30 (6): 1381-7).
PIM-2 is the second member of PIM kinase families.Functionally, noticed that PIM-2 and Akt/mTOR approach intersects, but it is independently adjusted.PIM-2 and Akt1 kinases all dependently to transcribe (Kane etc., Mol Cell Biol.2002 August by Cot kinase whose phosphorylated regulation NF κ B; 22 (16): 5962-74; Hammerman etc., Cancer Res.2004 November 15; 64 (22): 8341-8).Shown that PIM-2 expresses and maintained high-caliber NF-kB activity, and the activation of PIM-2 to NF-κ B is needed for its anti-apoptotic function.In addition, these Notes of Key Datas, the dependent NF kB activation of Cot by transcribing induction PIM-2 and occurring, but not as the direct result of the initial kinase cascade of acceptor.Multiple report display, in driving tumour occurs, PIM-2 can substitute PIM-1 to a certain extent or match with it.Because these two kinds of kinases have some targets (as Bad albumen), they are all as stoping the short survival kinase of apoptosis induction to work (Yan etc., J Biol Chem.2003 November 14; 278 (46): 45358-67; Aho etc., FEBS Lett.2004 July 30; 571 (1-3): 43-9).Because PIM-1 and PIM-2 all conducts (as FLT3 or Bcr-Abl intracellular signaling) inducible transcription by stream signal, so they can be cooperated and by v-Abl oncogene (Chen etc., Blood.2008 February 1 most important in B cell tumor transformation; 111 (3): 1677-85).Similar with PIM-1, the genetically modified coexpression inducing malignant of PIM-2 and c-Myc transforms (Allen etc., Oncogene.1997 September 4; 15 (10): 1133-41).In addition, as as shown in document, the effect that PIM-1 and PIM-2 cell cycle suppresses seems collaborative and accelerates cell proliferation and cell cycle progression, but only describes molecular mechanism (Dai etc., Prostate.2005 November 1 that PIM-1 kinases regulates the cell cycle in detail; 65 (3): 276-86; Chen etc., Mol Cancer Res.2005 August; 3 (8): 443-51).But, seem also to there are differences between these two kinds of kinases.Although recently about the publication of anoxic points out that it is formed and newfound effect in chemoresistance at solid tumor, there is no for the kinase whose similar report of PIM-2, therefore need to study this effect further.On the other hand, in the publication of Tamburini, emphasize the effect of PIM-2 in the phosphorylation (on Serine S65) of key 4EBP1 transcription factor (Tamburini etc., Blood.2009 August 20 especially; 114 (8): 1618-27).As shown in this publication, in clinical sample, the expression of PIM-1 is uncorrelated with above-mentioned discovery, provides PIM-1 and PIM-2 at the evidence regulating non-overlapped effect in the synthesis of 4EBP1 phosphorylation, Function protein matter and promotion tumor transformation.Fox and colleague have also reported similar discovery, highlight the keying action of PIM-2 kinases independent of the other places control translation of Akt/mTOR approach, and point out to suppress PIM-1 kinases as attractive possibility (Fox etc., Genes Dev.2003 August 1 of exploitation new therapy (especially in acute myelogene leukemia); 17 (15): 1841-54).
Similar with PIM-1, in several people's tumor types, report the process LAN of PIM-2.One of them famous report relates to the tumour that PIM-2 participates in hepatocellular carcinoma (hepatocellular carcinoma, HCC) and (Gong etc., J Surg Res.2009 May 1 occurs; 153 (1): 17-22).Research PIM-2 genetic expression and protein level thereof in human liver cancer tissue and HepG2 cell (human hepatocellular carcinoma clone).In these two kinds of situations, PIM-2 gene and protein expression, higher than the expression in the hepatic cell line L02 of immortalization, show its effect as Tumor biomarkers.Further experiment shows, PIM-2 expresses and kinase activity is that IL-3 is dependent; But its Apoptosis inhibitor effect is IL-3 dependent/non-dependent.Also find that the protection of PIM-2 to apoptosis is glucose dependency, thus by high concentration glucose and somatomedin the liver cell of tumor growth that holds there is the favourable condition expressing PIM-2, and after depriving glucose, PIM-2 can not stop apoptosis.So, once in liver cell process LAN, PIM-2 can be tumour occur in important factor.
PIM-3 is the 3rd member of PIM kinase families.Similar with PIM-2 and PIM-1, PIM-3 works in the mode of short survival, and it stops apoptosis by phosphoBad.But, with PIM-1/2 unlike, PIM-3 seems lower to the specificity of Ser112 residue, preferably phosphoric acid Ser136, Ser155 and Ser170 (Macdonald etc., BMC Cell Biol.2006 January 10; 7: 1).For phosphorylation Ser136 residue, PIM-3 is the most effective kinases, and this seems for phosphatising step subsequently and is vital with anti-apoptotic Bcl-XL protein-interacting.Therefore, find that PIM promotes 14-3-3 to combine to the phosphorylation of Bad and suppresses Bcl-XL to combine.With PIM-1 similarly, PIM-3 seems also to participate in promote that vascularization and blood vessel occur (Zippo etc., Blood.2004 June 15; 103 (12): 4536-44; Zhang etc., J Cell Physiol.2009 July; 220 (1): 82-90).Blood vessel relates to the physiological process going out neovascularity from existing angiogenic growth.This feature plays a significant role in tumour occurs, because before blood vessel usually occurs in transfer.Although blood vessel is the normal processes in g and D, however it to be also tumour be converted into the basic step of malignant state from dormant state.Found that in endotheliocyte, PIM-3 all highly expresses at mRNA and protein level, and this protein and cell pellets pseudopodium (lamelliopodia) focal adhesion kinase (FAK) (a kind of kinases participating in cell adhesion and diffusion process) are located altogether.FAK is usually located at the structure place being called as " focal adhension (focal adhesion) "; These are the polyprotein matter structures connecting extracellular matrix and cytoplasmic cell skeleton.In focal adhension kinetics between cell, it is raised as participant, and plays a role in mobility and cell survival.FAK also has tyrosine kinase activity, and is accredited as the substrate of oncogene protein at first.After processing by the cytochalasin D (cytochalasin D) destroying actinmicrofilament, from lamellipodium release PIM-3, this shows the strong interaction of PIM-3 and cytoskeleton.In addition, strike the migration of low PIM-3 Human Umbilical Vein Endothelial Cells by siRNA, breed and go out Buds formation there is significant effect.In view of this discovery, PIM-3 kinases is seemingly for the new target drone having prospect of blood vessel generation new inhibitor.
At several human cancers (mainly solid tumor, as gastrointestinal cancer, colorectal carcinoma or liver cancer) in observe PIM-3 process LAN, wherein the expression of PIM-3 seems or the mark of poor prognosis, and (Popivanova etc., Cancer Sci.2007 March is studied in its effect in pancreas adenocarcinoma occurs in more detail; 98 (3): 321-8; Zheng etc., J Cancer Res Clin Oncol.2008 April; 134 (4): 481-8).Find that PIM-3 is expressed in the malignant change of pancreas, and not to be expressed in normal pancreatic tissue (Li etc., Cancer Res.2006 July 1; 66 (13): 6741-7).Consistent with this discovery, PIM-3 mRNA and protein group are expressed in all detected human pancreatic cancer cell with becoming second nature.Strike low PIM-1 mRNA level in-site and cause apoptosis, this proves that PIM-3 is suppressing the keying action in pancreatic carcinoma apoptosis.In further experiment display pancreatic cell system PIM-3 expression by Ets-1 albumen and people PIM-3 gene-249bp extremely between-183bp the combination of 5 '-flanking region control (Li etc., Cancer Sci.2009 March; 100 (3): 396-404).Process LAN Ets-1 transcription factor can stimulate that PIM-3 is kinase whose to be transcribed and translate.These observationss show, abnormal PIM-3 can be induced to express, and stop apoptosis subsequently at human pancreatic cancer cell transcription factor Ets-1.Although PIM-3 is the kinase whose fact in cancer generation with the effect of new discovery, but the above results shows the important and diversified effect that PIM-3 can play in tumour occurs, and provide theoretical basis for developing the PIM-3 inhibitor being used for cancer therapy further.
DYRK1A/MNB kinases is the member of dual tyrosine phosphorylated regulation kinases (DYRK) family, the Serine of its catalysis in its substrate and the phosphorylation of threonine residues, and autophosphorylation in catalytic activation ring on tyrosine residues (Himpel etc., Biochem be on November 1, in J.2001; 359 (Pt 3): 497-505, Kentrup etc., J Biol Chem.1996 February 16; 271 (7): 3488-95).DYRK1A plays different effects between the growth period, by neuron proliferation with neural occur to play an important role in control brain grows (Becker FEBS J.2011Jan; 278 (2): 222, Tejedor FEBS J.2011Jan; 278 (2): 223-35).DYRK1A is relevant to the pathology of neurodegenerative disease higher than normal level.Especially some neurobiologys that the Dyrk1A process LAN that trisomy 21 connects relates to mongolism (Down syndrome) change, such as mental retardation (Park Cell Mol Life Sci.2009 October; 66 (20): 3235-40).Except it is except developmental effect, recognize that (Wegiel FEBS J.2011Jan the process LAN of DYRK1A in adult can cause the cognitive defect of mongolism and Alzheimer sample neurodegeneration gradually; 278 (2): 236-45).Observe in the mouse of DYRK1A process LAN, the enhancing of protein (dynamin (dynamin), amphibious vacuolar protein (amphiphysin), synaptic vesicle Phosphoric acid esterase (synaptojanin)) phosphorylation participating in Vesicle transport can cause synaptic function to be lacked of proper care (Murakami J Biol Chem.2006 August 18; 281 (33): 23712-24, Adayev Biochem Biophys Res Commun.2006 December 29; 351 (4): 1060-5, Xie PLoS One.2012; 7 (4): e34845).In addition, DYRK1A process LAN causes microtubule associated tau protein hyperphosphorylation, and forms neurofibrillary tangles subsequently, and this is that (Wegiel FEBS is January in year J.2011 for one of main pathological hallmark of alzheimer's disease or senile dementia; 278 (2): 236-45).Other substrates of DYRK1A are also accredited as the component of protein aggregate, this is the mark of neurodegenerative disease, Lewy corpusculum in such as, amyloid plaques in alzheimer's disease and Parkinson's disease and Lewy Body Dementia (Kim J Biol Chem.2006 November 3; 281 (44): 33250-7).Dyrk1 is phosphorylated human microtubule associated tau protein on Thr212 in vitro, described Thr212 be phosphorylated in fetus tau and in alzheimer's disease (AD) and Tau pathology (tauopathy) (comprising Pick's disease (Pick disease)) by the residue of hyperphosphorylation (Ferrer Neurobiol Dis.2005 November; 20 (2): 392-400).Recently confirmed that DYRK1A polymorphism changes risk (the JonesNeurodegener Dis.2012 that α synapse nucleoprotein related dementias occurs; 10 (1-4): 229-31).When compared with not ill human brain, in AD brain, the expression of Dyrk1A raises (Ferrer Neurobiol Dis.2005 November to some extent; 20 (2): 392-400; Kimura Hum Mol Genet.2007 January 1; 16 (1): 15-23).
Purpose of the invention and overview
The present inventor especially have been surprisingly found that formula (I) compounds exhibit goes out PIM1-3 kinases and the kinase whose strong inhibitory activity of DYRK as defined herein.
In first aspect, the present invention relates to formula (I) compound or pharmaceutically acceptable salt thereof:
Wherein
X 1be selected from nitro, cyano group, methyl, trifluoromethyl ,-C (=O) T 1,-C (=O) OT 4with-S (=O) 2t 4;
Z and X 2be selected from F, Cl, Br, I ,-C independently of one another 1-3alkyl and trifluoromethyl, prerequisite is Z and X 2be asynchronously-C 1-3alkyl;
X 3be selected from H ,-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 3 to 6 yuan of carbocyclic rings or heterocycle replaced, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced;
X 4do not exist, or be selected from-NR 4-and-N (R 4) (CH 2)-;
R 4be selected from H and-C 1-6alkyl;
Y 1be selected from H ,-C 1-6alkyl and 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is, if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, wherein said-C 1-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 5 to 6 yuan of saturated heterocyclics replaced, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced;
T 1, T 2and T 3be selected from H and-C independently of one another 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 7,-S (=O) 2oT 8with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 4-C 1-6alkyl, described-C 1-6alkyl is optionally independently selected from by F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 8,-S (=O) 2oT 7with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 5, T 6and T 7be selected from H and-C independently of one another 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced; And
T 8be selected from-C 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced.
In a preferred embodiment, X 1be selected from nitro, cyano group, methyl and trifluoromethyl.In one even more preferred, X 1be selected from nitro, cyano group and trifluoromethyl.Can particularly preferably be, X 1for nitro.
In a further preferred embodiment, Z and X 2be selected from F, Cl, Br, I, methyl and trifluoromethyl independently of one another, prerequisite is Z and X 2it is asynchronously methyl.
In a further preferred embodiment, Z and X 2be selected from F, Cl, Br, I and trifluoromethyl independently of one another.
In yet another preferred embodiment, Z and X 2be selected from F, Cl, Br and I independently of one another.In another preferred embodiment, Z and X 2be Br separately.
For X 3definition, can preferably, as X 3described 3 to the 6 yuan of saturated carbon rings defined or heterocycle be selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylenimine, oxyethane, thiirane, azetidine, trimethylene oxide, Thietane, tetramethyleneimine, tetrahydrofuran (THF), tetramethylene sulfide, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, tetrahydropyrans, thia hexanaphthene, piperazine, morpholine and thiomorpholine.
In yet another preferred embodiment, X 3be selected from-C 2-6alkyl ,-C 2-6thiazolinyl ,-C 2-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 2-6alkyl ,-C 2-6thiazolinyl and-C 2-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 3 to 6 yuan of saturated carbon rings or heterocycle replaced, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.Can particularly preferably be, X 3be selected from-C 2-6alkyl, described-C 2-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.In an even preferred embodiment, X 3be selected from ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl, wherein said ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl are optionally independently selected from-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-ST 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
In yet another preferred embodiment, X 3be selected from H ,-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl, wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.Can particularly preferably be, X 3be selected from H and-C 1-4alkyl, described-C 1-4alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.In an even preferred embodiment, X 3be selected from H, methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl, wherein said methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, sec-butyl are optionally independently selected from-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-ST 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
In yet another preferred embodiment, X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is by 3 to 6 yuan of carbocyclic rings or heterocyclic substituted, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.Can particularly preferably be, X 3be selected from-C 1-3alkyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-3alkyl is by 3 to 6 yuan of carbocyclic rings or heterocyclic substituted, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
In yet another preferred embodiment, X 3be 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.Can further preferably, X 3be 3 to 6 yuan of saturated heterocyclics, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of heterocycles are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.Can preferably, described 3 to 6 yuan of heterocycles be selected from ethylenimine, oxyethane, thiirane, azetidine, trimethylene oxide, Thietane, tetramethyleneimine, tetrahydrofuran (THF), tetramethylene sulfide, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, tetrahydropyrans, thia hexanaphthene, piperazine, morpholine and thiomorpholine.Also can preferably, described 3 to 6 yuan of ring selected from pyrrolidine, tetrahydrofuran (THF), tetramethylene sulfide, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, tetrahydropyrans, thia hexanaphthene, piperazine, morpholine and thiomorpholine.
In a further preferred embodiment, X 4not exist or for-NR 4-, wherein R 4be preferably H.
For Y 1definition, can preferably, as Y 1described 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic defined or heterocycle be selected from cyclobutyl, cyclopentyl, cyclohexyl, suberyl, azetidine, trimethylene oxide, Thietane, tetramethyleneimine, tetrahydrofuran (THF), tetramethylene sulfide, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, tetrahydropyrans, thia hexanaphthene, piperazine, morpholine, thiomorpholine, azepan, oxepane, thia suberane, homopiperazine, phenyl, pyrroles, furans, thiophene, imidazoles, pyrazoles, azoles, different azoles, thiazole, isothiazole, pyridine, pyrazine, pyrimidine and pyridazine.
In yet another preferred embodiment, X 4-NR 4-and Y 1be selected from H and-C 1-6alkyl, wherein said-C 1-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.Can particularly preferably be, X 4-NR 4-and Y 1-C 1-4alkyl, wherein said-C 1-4alkyl is optionally independently selected from-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.In this context, can preferably, R 4, T 1, T 2and T 3be selected from H.
In yet another preferred embodiment, Y 1be 4 to 7 yuan of saturated or undersaturated aromatic carbocyclic or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.In this embodiment, can particularly preferably be, X 4do not exist.
In yet another preferred embodiment, Y 1be 4 to 7 yuan of saturated carbon rings or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.Can preferably, described 4 to 7 yuan of saturated carbon rings or heterocycle be selected from cyclobutyl, cyclopentyl, cyclohexyl, suberyl, azetidine, trimethylene oxide, Thietane, tetramethyleneimine, tetrahydrofuran (THF), tetramethylene sulfide, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, tetrahydropyrans, thia hexanaphthene, piperazine, morpholine, thiomorpholine, azepan, oxepane, thia suberane and homopiperazine.In this embodiment, can preferably, X 4do not exist.
In yet another preferred embodiment, Y 1be 4 to 7 yuan of saturated heterocyclics, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of heterocycles are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.Can preferably, described 4 to 7 yuan of saturated heterocyclics be selected from azetidine, trimethylene oxide, Thietane, tetramethyleneimine, tetrahydrofuran (THF), tetramethylene sulfide, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, tetrahydropyrans, thia hexanaphthene, piperazine, morpholine, thiomorpholine, azepan, oxepane, thia suberane and homopiperazine.In this embodiment, can particularly preferably be, X 4do not exist.
In an especially preferred embodiment, X 4do not exist and Y 14 to 7 yuan of saturated nitrogen heterocyclic rings, be preferably selected from azetidine, tetramethyleneimine, tetrahydroglyoxaline pyridine, pyrazolidine, azoles alkane, different azoles alkane, thiazolidine, isothiazolidine, piperidines, piperazine, morpholine, thiomorpholine, azepan and homopiperazine, more preferably be selected from azetidine, tetramethyleneimine, piperidines, piperazine, morpholine, azepan and homopiperazine, and be most preferably piperazine, prerequisite is the tie point on described heterocycle is nitrogen, and wherein said 4 to 7 yuan of heterocycles are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
In yet another preferred embodiment, X 4be selected from-NR 4-and-N (R 4) (CH 2)-, and Y 1be 4 to 7 yuan of saturated or undersaturated aromatic carbocyclic or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of oxo replaced.
In a further preferred embodiment, T 1, T 2and T 3be selected from H and-C independently of one another 1-3alkyl, described-C 1-3alkyl is optionally independently selected from-N (T 5) (T 6) and-OT 7one or more substituting group replaced, wherein T 5, T 6and T 7preferably independently be selected from H and-C 1-3alkyl.
In yet another preferred embodiment, T 4-C 1-3alkyl, described-C 1-3alkyl is optionally independently selected from-N (T 5) (T 6) and-OT 7one or more substituting group replaced, wherein T 5, T 6and T 7preferably independently be selected from H and-C 1-3alkyl.
In yet another preferred embodiment, T 5, T 6and T 7be selected from H and-C independently of one another 1-3alkyl, described-C 1-3alkyl is optionally independently selected from one or more substituting group that is amino and hydroxyl and replaces.
In a further preferred embodiment, T 8be selected from-C 1-3alkyl, described-C 1-3alkyl is optionally independently selected from one or more substituting group that is amino and hydroxyl and replaces.
In an especially preferred embodiment, X 1be selected from nitro, cyano group, methyl, trifluoromethyl ,-C (=O) T 1,-C (=O) OT 4with-S (=O) 2t 4; Z and X 2be selected from F, Cl, Br, I and trifluoromethyl independently of one another; X 3be selected from H ,-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl, wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced; And Y 1be 4 to 7 yuan of saturated or undersaturated aromatic carbocyclic or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7with-N (T 2) (T 3) one or more substituting group replaced.
In another particularly preferred embodiment, X 1be selected from nitro, cyano group, methyl, trifluoromethyl ,-C (=O) T 1,-C (=O) OT 4with-S (=O) 2t 4; Z and X 2be selected from F, Cl, Br, I and trifluoromethyl independently of one another; X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is by 3 to 6 yuan of carbocyclic rings or heterocyclic substituted, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced; And Y 1be 4 to 7 yuan of saturated or undersaturated aromatic carbocyclic or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7with-N (T 2) (T 3) one or more substituting group replaced.
In the certain preferred embodiments (A) of first aspect, the present invention relates to:
(A) 1. formula (I) compound or pharmaceutically acceptable salt thereof:
Wherein
X 1be selected from nitro, cyano group, methyl, trifluoromethyl ,-C (=O) T 1,-C (=O) OT 4with-S (=O) 2t 4;
Z and X 2be selected from F, Cl, Br, I ,-C independently of one another 1-3alkyl and trifluoromethyl, prerequisite is Z and X 2be asynchronously-C 1-3alkyl;
X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 3 to 6 yuan of saturated carbon rings or heterocycle replaced, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced;
X 4do not exist, or be selected from-NR 4-and-N (R 4) (CH 2)-;
R 4be selected from H and-C 1-6alkyl;
Y 1be selected from H ,-C 1-6alkyl and 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is, if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, wherein said-C 1-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 5 to 6 yuan of saturated heterocyclics replaced, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced;
T 1, T 2and T 3be selected from H and-C independently of one another 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 7,-S (=O) 2oT 8with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 4-C 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 8,-S (=O) 2oT 7with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 5, T 6and T 7be selected from H and-C independently of one another 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced; And
T 8be selected from-C 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced.
(A) compound 2. Gen Ju (A) 1, wherein X 1be selected from nitro, cyano group, trifluoromethyl ,-C (=O) T 1with-S (=O) 2t 4.
(A) 3. according to (A) 1 or the compound described in (A) 2, wherein X 1be selected from nitro, cyano group and trifluoromethyl.
(A) 4. according to the compound according to any one of (A) 1 to (A) 3, wherein X 1it is nitro.
(A) 5. according to the compound according to any one of (A) 1 to (A) 4, wherein Z and X 2be selected from F, Cl, Br, I and trifluoromethyl independently of one another.
(A) 6. according to the compound according to any one of (A) 1 to (A) 5, wherein Z and X 2be selected from F, Cl, Br and I independently of one another.
(A) 7. according to the compound according to any one of (A) 1 to (A) 6, wherein Z and X 2br.
(A) 8. according to the compound according to any one of (A) 1 to (A) 7, wherein X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl, wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
(A) 9. according to the compound according to any one of (A) 1 to (A) 8, wherein X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl.
(A) 10. according to the compound according to any one of (A) 1 to (A) 9, wherein X 3-C 1-6alkyl, preferably-C 1-3alkyl or-C 1-2alkyl, more preferably sec.-propyl or ethyl.
(A) 11. according to the compound according to any one of (A) 1 to (A) 10, wherein Y 1be 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
(A) 12. according to the compound according to any one of (A) 1 to (A) 11, wherein Y 1be 4 to 7 yuan of saturated carbon rings or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
(A) 13. according to (A) 11 or the compound described in (A) 12, wherein X 4do not exist.
(A) 14. according to the compound according to any one of (A) 1 to (A) 13, wherein X 4do not exist, and Y 1be 6 yuan of saturated carbon rings or heterocycle, wherein said 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced.
(A) 15. according to the compound according to any one of (A) 1 to (A) 14, wherein X 4do not exist, and Y 1be 6 yuan of saturated heterocyclics, wherein said 6 yuan of heterocycles are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced.
(A) 16. according to the compound according to any one of (A) 1 to (A) 15, wherein X 4do not exist, and Y 1piperidines or piperazine.
(A) 17. compounds Gen Ju (A) 1, wherein said compound is selected from:
The bromo-1-ethyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole;
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole;
(3S)-1-(the bromo-1-ethyl of 5,6-bis--4-nitro-1H-1,3-benzodiazole-2-base) piperidines-3-amine;
The bromo-2-of 5,6-bis-[(2S)-2-methylpiperazine-1-yl]-4-nitro-1-(propane-2-base)-1H-1,3-benzodiazole; And
The bromo-4-nitro of 5,6-bis--2-(piperidin-4-yl)-1-(propane-2-base)-1H-1,3-benzodiazole.
(A) 18. compounds according to A (17), wherein said compound is selected from:
The bromo-1-ethyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole;
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole; And
The bromo-4-nitro of 5,6-bis--2-(piperidin-4-yl)-1-(propane-2-base)-1H-1,3-benzodiazole.
In another preferred embodiment, pharmacologically acceptable salt is selected from: hydrochloride, hydrobromate, hydriodate, nitrate, vitriol, hydrosulfate, phosphoric acid salt, acid phosphate, γ-picolinic acid salt, acetate, lactic acid salt, salicylate, Citrate trianion, tartrate, pantothenate, bitartrate, ascorbate salt, succinate, maleate, gentisate, fumarate, gluconate, glucuronate (glucaronate), saccharate, formate, benzoate, glutaminate, mesylate, esilate, benzene sulfonate, tosilate and pamoate.Hydrochloride can be particularly preferred.
In second aspect, the present invention relates to the pharmaceutical composition of the compound (comprising all preferred embodiments as mentioned above) comprised according to first aspect as listed above.The certain preferred embodiments of second aspect is relate to when describing of the present invention in more detail.
In the third aspect, the present invention relates to according to pharmaceutical composition of the present invention, it is used for the treatment of specified disease, particularly Therapeutic cancer, autoimmune disease and inflammatory diseases (as also listed following in more detail).
For the third aspect and above compound listed in embodiment (A), the compound of embodiment (A) is used for the treatment of leukemia (such as acute myelogene leukemia (AML)), Huo Qijin and non-Hodgkin lymphoma (such as dispersivity large B cell lymphoid tumor (DLBCL)) in a preferred embodiment of the third aspect, and multiple myeloma (MM).
In fourth aspect, the present invention relates to for regulating or adjusting and preferably suppress the method for serine/threonine or Tyrosylprotein kinase, described kinases is preferably selected from PIM1-3, FLT3 and DYRK1A, and be more preferably selected from PIM1-3 and DYRK1A or be selected from PIM1-3 and FLT3 (comprising FLT3 wild-type and FLT3 saltant type kinases), described serine/threonine or Tyrosylprotein kinase is wherein made to be exposed at least one formula (I) compound as defined above (comprising all preferred embodiments as defined above) or its pharmacologically acceptable salt, wherein said method is preferably carried out outside human or animal's health.
In the 5th, the present invention relates to formula as defined above (I) compound (comprising all preferred embodiments as defined above) or its pharmacologically acceptable salt as serine/threonine or tyrosine kinase modulators and preferably as the purposes of inhibitor, wherein said kinases is preferably selected from PIM1-3, FLT3 and DYRK1A, and is more preferably selected from PIM1-3 and DYRK1A.
Accompanying drawing explanation
Fig. 1: after compound 1A incubated cell of the present invention, the PIM-kinase biomarker thing (in detail see embodiment 3.14) in MV4-11 cell.
Fig. 2: after compound 2A incubated cell of the present invention, the PIM-kinase biomarker thing (in detail see embodiment 3.14) in MV4-11 cell.
Fig. 3: after compound 1BI incubated cell of the present invention, the PIM-kinase biomarker thing (in detail see embodiment 3.14) in MV4-11 cell.
Fig. 4: after compound 1BI incubated cell of the present invention, the PIM-kinase biomarker thing (in detail see embodiment 3.14) in MOLM-16 cell.
Fig. 5: the gross tumor volume kinetics and the body weight kinetics (in detail see embodiment 3.15) that use the MOLM16 heterograft of compound 2A.
Fig. 6: be used alone or combinationally use gross tumor volume kinetics and the body weight kinetics (in detail see embodiment 3.15) of the MV-4-11 heterograft of compound 26A with cytosine arabinoside.
Detailed Description Of The Invention
The present inventor especially successfully identifies and effectively suppresses PIM1-3 kinases and the kinase whose new compound of DYRK1A.Therefore compound of the present invention can be used for the treatment of cancer, autoimmune disease and inflammatory diseases especially.
Before describing embodiments more of the present invention in more detail, introduce to give a definition.
1. definition
general definition
Unless the context clearly indicates, otherwise as the noun not having numeral-classifier compound to modify that uses in the specification and in the claims represent one/kind or more individual/kind.Unless the context clearly indicates, otherwise the noun not having numeral-classifier compound to modify used herein represents one/kind or more/kind.
In context of the present invention, term " about " and " approximately " represent that the tolerance range still guaranteeing the technique effect of discussed feature that it will be appreciated by those skilled in the art that is interval.This term ordinary representation departs from specified numerical value ± 10%, preferably ± 5%.
It is to be appreciated that it is nonrestrictive that term " comprises ".With regard to object of the present invention, think that term " by ... composition " is a preferred embodiment of term " comprising ... ".If a group (group) is defined as comprising at least one fixed number object embodiment hereinafter, then this is also intended to comprise the group be preferably only made up of these embodiments.
It can be the hydrocarbon chain of straight or branched that term " alkyl " refers to, and it comprises the carbon atom specified number.Such as, C 1-6represent that this group can have 1 to 6 (comprising end value) carbon atom wherein.If do not indicate the carbon atom of alkyl, term " alkyl " refers to C 1-15alkyl, preferred C 1-10alkyl, and be more preferably C 1-4alkyl.
Generally speaking, the carbonatoms be present in given group is designated as " C x-y", wherein x and y is lower limit and the upper limit respectively.Such as, " C is appointed as 1-5" group comprise 1 to 5 (comprising end value) carbon atom.Carbon number as used in definition herein refers to carbon skeleton and carbon side chain, but does not comprise substituent carbon atom.The general example of alkyl comprises methyl, ethyl, propyl group, sec.-propyl, butyl, normal-butyl, isobutyl-, sec-butyl, the tertiary butyl and amyl group.Such as, term " C 1-3alkyl " refer to the straight or branched stable hydrocarbon comprising 1 to 3 carbon atom.C 1-3the example of alkyl includes, but are not limited to: methyl, ethyl, propyl group and sec.-propyl.Such as, term " C 6-10alkyl " refer to the straight or branched stable hydrocarbon comprising 6 to 10 carbon atoms.C 6-10the example of alkyl includes, but are not limited to: hexyl, octyl group and decyl.
" thiazolinyl " is the hydrocarbon chain with at least one (preferably only one) carbon-to-carbon double bond." alkynyl " is the hydrocarbon chain with at least one (preferably only one) carbon-to-carbon triple bond.
Term " heterocycle " refers to and comprises carbon atom and at least one heteroatomic ring texture.Term used herein " heteroatoms " preferably refers to nitrogen-atoms, sulphur atom and Sauerstoffatom.Heterocycle generally can comprise different heteroatomss.For the present invention, can preferred nitrogen as heteroatoms.In addition, for the present invention, can preferably, heterocycle comprises one or two heteroatoms.If mention specific heterocycle (such as piperazine) herein, this is mentioned and should be understood to relate to the conventional of heterocycle described in chemical field and the structure limited.
If such as mentioned herein " 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle ", it is to be appreciated that term " aromatics " only combinationally uses with term " undersaturated "; Therefore, above-mentioned definition also can be considered to the abstract definition of " 4 to 7 yuan of saturated non-aromatic or 4 to 7 yuan of undersaturated aromatic carbocyclic or heterocycle ".Certainly, the term " aromatics " used in abstract definition does not combine with term " saturated " and reads, because this is mentioned generation non-existent " saturated aromatic carbocyclic or heterocycle ".
Term " halogen " comprises fluorine, bromine, chlorine or iodine.Term " amino " expression-NH 2, term " hydroxyl " is-OH, and term " sulfydryl " is-SH, and term " nitro " is-NO 2, term " cyano group " is-CN and " oxo " is=O." carbon side chain " or " branched-chain alkyl " mean one or more alkyl (such as methyl, ethyl or propyl group) and substitute-CH in linear alkyl chain 2one or two hydrogen of-group.
If substituting group is not defined as being final substituting group, but as bridging substituting group (bridging substituent) (such as, X 4"-NR 4(CH 2)-", defines), the direction that this definition is preferred for compound of the present invention is one-piece construction from left to right.This means, such as, for "-NR 4(CH 2)-", nitrogen is connected to benzimidazole moiety, and-CH 2-be connected to substituting group Y 1.
If be referred to the tie point on heterocycle herein, this refers to the atom in the heterocycle be connected with the rest part of this compound.Under certain situation of the present invention, this can refer to X 4at Y 1position is connected to heterocycle, or, if X 4do not exist, refer to the position 2 of benzimidazole moiety at Y 1position is connected to heterocycle (direct key).In other situations of the present invention, this may refer to heterocycle with X 3position is connected to the nitrogen-atoms of benzimidazole moiety.
The present invention disclosed herein is intended to all pharmacologically acceptable salts containing disclosed compound, particularly above involved salt.In addition pharmacologically acceptable salt comprises metal-salt, such as sodium salt, sylvite, cesium salt etc.; Alkaline earth salt, such as calcium salt, magnesium salts etc.; Organic amine salt, such as triethylamine salt, pyridinium salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexyl amine salt, N, N '-dibenzyl ethylenediamine salt etc.; Inorganic acid salt, such as hydrochloride, hydrobromate, vitriol, phosphoric acid salt etc.; Organic acid salt, such as formate, acetate, trifluoroacetate, maleate, fumarate, tartrate etc.; Sulfonate, such as mesylate, benzene sulfonate, tosilate etc.; Amino acid salts, such as arginic acid salt, l-asparagine salt, glutaminate etc.Particularly preferred pharmacologically acceptable salt can be selected from hydrochloride, hydrobromate, hydriodate, nitrate, vitriol, hydrosulfate, phosphoric acid salt, acid phosphate, γ-picolinic acid salt, acetate, lactic acid salt, salicylate, Citrate trianion, tartrate, pantothenate, bitartrate, ascorbate salt, succinate, maleate, gentisate, fumarate, gluconate, glucuronate (glucaronate), saccharate, formate, benzoate, glutaminate, mesylate, esilate, benzene sulfonate, tosilate and pamoate.Hydrochloride is particularly preferred for the compounds of this invention.
Compound disclosed herein can comprise one or more asymmetric center, and therefore can cause enantiomorph, diastereomer and other stereoisomer forms.Except as otherwise noted, otherwise the present invention is also intended to form containing all these possible forms and its racemize and fractionation and composition thereof.When compound described herein contains alkene double bond or other geometry asymmetric centers, except as otherwise noted, otherwise its be intended to comprise E and Z two kinds of geometrical isomers.The present invention is also intended to contain all tautomers.
Term as used in this article " steric isomer " is the generic term of only different on the spatial orientation of its atom all isomer of individual molecule.It comprises the isomer (diastereomer) with the compound more than a chiral centre of enantiomorph and non-mirror image each other.Term " chiral centre " refers to and is connected with four not isoplastic atoms.Therefore term " enantiomorph " or " enantiomorph " refer to overlappingly also can not have optically active molecule with its mirror image, and wherein said enantiomorph makes the plane of polarized light rotate to a direction, and its mirror image makes the plane of polarized light rotate in the opposite direction.Term " racemic " refers to the mixture of equal portions enantiomer, and it is without optical activity.Term " splits (resolution) " and refers to separation or concentrate or exhaust the one in two kinds of enantiomeric forms of molecule.
" pharmaceutically active agents " used herein refers to the compound of the response effectively regulating human or animal in vivo.When mentioning that compound is " unique pharmaceutically active agents ", this activity being intended to describe relative medicine composition is attributable simply to described promoting agent.
Term used herein " pharmaceutically acceptable vehicle " refers to the compound be generally comprised within pharmaceutical composition known to the skilled.Such compound or vehicle are exemplarily listed below.Consider the definition " pharmaceutically active agents " provided above, pharmaceutically acceptable vehicle can be defined as without pharmaceutical active.
according to the description of pharmaceutical composition of the present invention
Can prepare pharmaceutical composition according to the present invention for per os (oral), suck (buccal), intranasal, per rectum, locally, through skin or parenteral administration.Can preferred oral administration.Also can preferred parenteral administration and it comprises intravenously, intramuscular or subcutaneous administration.Should such as, pharmaceutically effectively to measure the compound used according to formula (I), the amount hereinafter listed.
Pharmaceutical composition of the present invention also can be represented as preparation or formulation.Hereinafter, formula (I) compound can also be represented as (medicine) promoting agent or active compound.
Pharmaceutical composition can be solid or liquid dosage form, or can have intermediate dosage form, such as, especially depends on the gel sample feature of route of administration.
Generally speaking, formulation of the present invention can comprise the multiple pharmaceutically acceptable vehicle function of realization selected for described formulation according to it.In implication of the present invention, " pharmaceutically acceptable vehicle " can be any material for the preparation of pharmaceutical dosage form, comprises coating material, film forming material, weighting agent, disintegrating agent, release regulation material, solid support material, thinner, tamanori and other auxiliary agents.General pharmaceutically acceptable vehicle comprises the material as sucrose, N.F,USP MANNITOL, sorbyl alcohol, starch and starch derivative, lactose and lubricant (such as Magnesium Stearate), disintegrating agent and buffer reagent.
Term " carrier " represents pharmaceutically useful organic or inorganic carrier substance, and activeconstituents and its combination are so that use.Suitable pharmaceutically acceptable carrier comprises such as water, salts solution, alcohol, oil (preferably vegetable oil), polyoxyethylene glycol, gelatin, lactose, amylose starch, Magnesium Stearate, tensio-active agent, perfume oil, fatty acid glycerine one ester and fatty acid diglyceride, oil (petroethral) fatty acid ester, Walocel MT 20.000PV, polyvinylpyrrolidone etc.And if pharmaceutical composition can be expected by sterilizing, can mix with auxiliary agent, such as lubricant, sanitas, stablizer, wetting agent, emulsifying agent, affect the salt of osmotic pressure, buffer reagent, tinting material, correctives and/or aromatoising substance etc., these auxiliary agents not with active compound generation adverse reaction.
If the present invention considers liquid dosage form, then these formulations can comprise the pharmaceutically useful emulsion, solution, suspensoid and the syrup that comprise inert diluent (such as water) conventional in the art.These formulations can comprise such as Microcrystalline Cellulose to give volume, alginic acid or sodiun alginate as suspending agent, methylcellulose gum as viscosity increaser and sweetener/correctives.
Use for parenteral, specially suitable supporting agent is made up of solution (preferred oiliness or aqueous solution) and suspensoid, emulsion or implant.Pharmaceutical preparation for parenteral administration is particularly preferred and comprises the aqueous solution of formula (I) compound of water-soluble form.In addition, the suspensoid of formula (I) compound can be prepared as suitable oily injection suspensoid.Suitable lipophilic solvent or supporting agent comprise fatty oil (such as sesame oil), or Acrawax (such as ethyl oleate or triglyceride level), or liposome.Aqueous inj ection suspensions can comprise the material improving suspensoid viscosity, such as Xylo-Mucine, sorbyl alcohol or dextran.
Particularly preferred formulation is the injectable formulation of formula (I) compound.Therefore, suitable dispersion agent, wetting agent and/or suspending agent is used such as can be formulated as water-based or the Oil suspensions of sterile injectable according to known technology.Sterile injectable preparation can also be sterile injectable solution agent in the nontoxic acceptable thinner of parenteral or solvent or suspensoid.Wherein spendable acceptable supporting agent and solvent be water and wait open sodium chloride solution.Aseptic oil is also used as solvent or suspending medium usually.
By such as this compound to be mixed the suppository of formula (I) compound used for the preparation of per rectum with suitable non-irritating excipient (triglyceride level of such as cocoa butter, synthesis and polyoxyethylene glycol).Described non-irritating excipient is at room temperature solid, but is liquid under rectal temperature, they will be melted in the rectum and from described suppository, discharge the compound according to formula (I).
Use for by suction, can use suitable propellent (such as Refrigerant 12, trichlorofluoromethane, dichloro tetrafluoro ethane, carbonic acid gas or other suitable gas), making can easily to send from the aerosol of pressurized package or the form of spraying gun according to compound of the present invention.In the case of a pressurized aerosol, by arranging quantitative delivery valve to determine dose unit.(the such as gelatin) capsule for using in sucker or insufflator and medicine box can be prepared, the powdered mixture of its inclusion compound and suitable powdered substrate (such as lactose or starch).
Oral can be liquid or solid and comprise such as tablet, lozenge, pill, capsule, powder, effervescent formulation, dragee and granule.Pharmaceutical preparation for oral administration can obtain as solid excipient, optionally grinds gained mixture and the mixture of processing granular agent, if necessary, then obtains tablet or dragee label after adding suitable auxiliary agent.Suitable vehicle is that weighting agent is such as sugared especially, comprises lactose, sucrose, N.F,USP MANNITOL or sorbyl alcohol; Cellulose preparation, such as W-Gum, wheat starch, Starch rice, yam starch, gelatin, tragakanta, methylcellulose gum, Vltra tears, Xylo-Mucine and/or polyvinylpyrrolidone (PVP).If desired, disintegrating agent can be added, such as cross-linked polyvinylpyrrolidone, agar or alginic acid or its salt (such as sodiun alginate).Oral can be mixed with guarantees release type (I) compound or sustained release formula (I) compound immediately.
Solid dosage can comprise film-coat.Such as, formulation of the present invention can be so-called film coated tablet form.Capsule of the present invention can be two-piece type hard gelatin capsule, two-piece type hydroxypropyl methylcellulose capsules, by plant or the two-part capsules made based on the Mierocrystalline cellulose of plant or the two-part capsules be made up of polysaccharide.
Can be mixed with for topical application according to formulation of the present invention.Can be local nasal spray, sublingual administration form and Co ntrolled release and/or sustained release skin patch for this suitable pharmaceutical administration forms used.Use for sucking, composition can adopt the form of tablet or the lozenge prepared in a usual manner.
Composition can exist easily with the form of unitary dose easily and prepare by method known in any pharmaceutical field.Described method can comprise the step making compound combined with the carrier forming one or more of ancillary component.Generally speaking, by making compound evenly and closely with liquid vehicle, fine particle solid carrier or both are combined, then (if necessary) product is shaped prepare described composition.Liquid dosage unit is bottle (vial) or ampoule.Solid dosage unit is tablet, capsule and suppository.
To people patient, can by formula (I) compound to be about 0.001mg to about 5000mg every day, be about 0.01mg to about 100mg preferred every day, the amount being more preferably about 0.1mg to about 50mg every day is used to patient.
the indication of the compounds of this invention can be used
Compound according to the present invention can be used for treating and is selected from following disease: myelogenous leukemia (acute and chronic), Acute Lymphoblastic Leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myeloproliferative disease, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, non-Hodgkin lymphoma (malignant lymphoma), the gland cancer of kidney, lymphoma, leukemia, the wilms' tumor of kidney, renal cell carcinoma, carcinoma of renal pelvis, nephroncus, teratoma, sarcoma, the squamous cell carcinoma of bladder and urethra, transitional cell carcinoma, gland cancer, prostatic sarcoma, the spermocytoma of testis, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, mesenchymal cell cancer, fibroma, fibroadenoma, adenomatoid tumor, lipoma, the angiosarcoma of heart, fibrosarcoma, rhabdosarcoma, liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma and teratoma, the astrocytoma of brain, myeloblastoma, glioma, ependymoma, gonioma [pinealoma], glioblastoma multiforme, mesoglioma, Schwann sheath knurl, retinoblastoma, congenital tumor, the neurofibroma of spinal cord, meningioma, glioma, sarcoma, the osteoma of cranium, vascular tumor, granuloma, vitiligoidea (xanthoma), osteitis deformans, meningeal meningioma, meninges sarcoma, gliomatosis, bronchially do not break up minicell squamous cell carcinoma, do not break up maxicell squamous cell carcinoma, gland cancer, alveolar cell carcinoma, bronchial adenoma, sarcoma, lymphoma, chondroma progonoma (chondromatous hanlartoma), mesothelioma, the lymphoma of small intestine, carcinoid tumor, Kaposi sarcoma, leiomyoma, vascular tumor, lipoma, neurofibroma, fibroma, the gland cancer of large intestine, tubular adenoma, villous adenoma, progonoma (hamartoma), leiomyoma, the squamous cell carcinoma of oesophagus, leiomyosarcoma, lymphoma, the lymphoma of stomach, leiomyosarcoma, the duct adenocarcinoma of pancreas, insulinoma, glucagonoma of pancreas, gastrinoma, carcinoid tumor, vasoactive intestinal polypeptide knurl (vipoma), the hepatocellular carcinoma of liver, cholangiocarcinoma, hepatoblast knurl, angiosarcoma, adenoma, vascular tumor, osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing sarcoma, malignant lymphoma are (such as, reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochronfroma) (such as, osteocartilaginous exostosis), benign chondromas, chondroblastoma, chondromyxoid fibroma, osteoid osteoma and giant cell tumor, carcinoma of endometrium, cervical cancer, uterine cervix atypical hyperplasia before tumour, the ovarian cancer of ovary such as, serous cystadenocarcinoma, mucus cystadenocarcinoma, non-classified cancer, granulosa-thecoma (granulosa-thecal cell tumor), Sai-Lai glucagonoma (Sertol/Leydig cell tumor), dysgerminoma, malignant teratoma, the squamous cell carcinoma of vulva, intraepithelial carcinoma, gland cancer, fibrosarcoma, melanoma, the clear cell carcinoma of vagina, squamous cell carcinoma, botryoid sarcoma (such as, embryonal rhabdomyosarcoma), carcinoma of fallopian tube, mammary cancer, and malignant melanoma, rodent cancer, squamous cell carcinoma, Kaposi sarcoma, mole dysplastic nevus, lipoma, vascular tumor, dermatofibroma, keloid (keloid), marrow graft rejection, rheumatoid arthritis, psoriatic, type i diabetes and multiple sclerosis.
Because the compounds of this invention is PIM kinase inhibitor, so it can be used for the treatment of PIM kinase-associated conditions especially.Therefore, the compounds of this invention can be used for Therapeutic cancer, particularly Hematopoietic Malignancies, such as disseminated B-cell lymphoma, chronic lymphocytic leukemia and acute myelogene leukemia, follicular lymphoma (FL) and chronic bone-marrow-derived lymphocyte leukemia (B-CLL), dispersivity large B cell lymphoid tumor (DLBCL), the non-Hodgkin lymphoma that AIDS is relevant, the B cell NHL of HCV infection, primary central nervous system lymphoma (PCNSL), tie outer DLBCL, primary cutaneous marginal zone B-cell lymphoma (PCMZL), Primary Mediastinal large B cell lymphoid tumor (PMLBCL), acute myeloid leukaemia (AML), chronic myelogenous leukemia, aggressive Head and neck squamous cell carcinoma (HNSCC), solid tumor, such as prostate cancer, carcinoma of the pancreas, gastrointestinal cancer, colorectal carcinoma, liver cancer, and hepatocellular carcinoma (HCC).In addition, described compound can be used for treatment inflammatory diseases, particularly rheumatoid arthritis, lupus, multiple sclerosis and inflammatory bowel.
Compounds more of the present invention not only suppress PIM kinases, and suppress FLT3 kinases.When mentioning FLT3 kinases in this application, this means to comprise its mutant forms.FLT3 (FMS sample Tyrosylprotein kinase) acute myeloid leukaemia (AML, its be in adult modal type of leukemia and account for 20% of leukemia of children case) pathogenesis in play vital effect.Usually to process LAN frequent in AML patient and the FLT3 of sudden change (such as usually relevant to poor prognosis ITD suddenlys change) kinase whose suppression is very promising target for treatment.Except AML being treated to useful FLT3 self suppression, should be the mode especially expected worked to Malignancy to the combination of FLT3 and the PIM inhibit activities at identical signal transduction path, this contributes to such as overcoming resistance.Therefore, PIM kinases is suppressed and FLT3 is kinase whose can be used for the treatment of AML especially according to compound of the present invention; It especially can be preferred for the AML patient that treatment has ITD sudden change (in FLT3 D835H, D835Y or N841I).
Describe the effect of DYRK1 in cancer.DYRK1A strengthens the transcriptional activity of Gli1 (the oncogene homologue 1 that glioma is relevant), described Gli1 is the transcription factor for hedgehog intracellular signaling end effect thing, described hedgehog intracellular signaling is that embryo occurs, stem cell maintains and tumorigenic critical path (J.Med.Chem., 2009,52 (13), 3829-3845).DYRK1A works (FEBS J., 2008,275 (24), 6268-6280) as the negative regulatory factor of apoptosis.Therefore, propose in cancer cells and suppress DYRK1A activity to be prevent cancer to be correlated with the New Policy of poorer prognosis, it demonstrates the resistance to short apoptotic stimulus.DYRK1A also have activated STAT3, described STAT3 in kinds cancer process LAN representative for hindering interesting target (Curr Cancer Drug Targets.2010 February of cancer progression; 10 (1): 117-26; AnticancerAgents Med Chem.2010 September; 10 (7): 512-9.).Therefore, the compounds of this invention can be used for Therapeutic cancer, particularly glioblastoma, mammary cancer, glioma, melanoma, the esophageal carcinoma, carcinoma of the pancreas and nonsmall-cell lung cancer.
Also think that DYRK1A relates to Neural Differentiation (Neurobiol Dis.2012 April; 46 (1): 190-203).The effect of DYRK1A kinases in neurodegeneration is known, therefore also can by the compounds for treating alzheimer's disease according to the application, mongolism and other Tau pathologies, such as, on Progressive symmetric erythrokeratodermia core, (FEBS is January in year J.2011 for paralysis, Pick's disease, chronic trauma encephalopathic and frontotemporal dementia; 278 (2): 236-45; J Neuropathol Exp Neurol.2011 January; 70 (1): 36-50).DYRK1A kinases is (J Biol Chem.2006 November 3 day relevant to the generation of alpha-synapse nucleoprotein dementia (such as Lewy body dull-witted and Parkinson's disease dementia) pathological condition also; 281 (44): 33250-7; Neurodegener Dis.2012; 10 (1-4): 229-31).
Most preferably, the compounds of this invention can be used for treating and is selected from following disease: leukemia (comprising Acute Lymphoblastic Leukemia, acute myelogene leukemia and chronic lymphocytic leukemia), lymphoma, myelomatosis, myeloproliferative disease, allograft rejection, inflammatory bowel, multiple sclerosis, psoriatic, rheumatoid arthritis, systemic lupus erythematous, alzheimer's disease and mongolism.
Relate in the preferred embodiment of pharmaceutical composition of the present invention at one, described pharmaceutical composition comprises the described compound as only pharmaceutically active agents.
Or except described compound, described pharmaceutical composition also comprises the other drug alone promoting agent of at least one.As mentioned above, cancer, autoimmune disease or inflammatory diseases or neurodegenerative disease can be used for the treatment of especially, to make to exist in addition the other drug alone promoting agent of at least one that is used for the treatment of such specified disease according to pharmaceutical composition of the present invention.
In addition, compound of the present invention can be used as adjuvant with such as Therapeutic cancer.It can use with one or more of other drug regimen, such as, by identical or that the different mechanism of action works chemotherapeutic.The embodiment part of the application listed in by such medicine, and it comprises two kinds of targeting agents, the kinase inhibitor of such as PI3K/Akt/mTOR approach or JAK/STAT approach and standard chemotherapeutic agents (such as cytosine arabinoside and vosaroxin).Especially, the compound of above listed certain preferred embodiments (A) can with chemotherapeutic (such as, PI3K inhibitor, jak kinase inhibitor, cytosine arabinoside, vosaroxin and composition thereof) combine for cancer therapy (such as, being used for the treatment of acute myelogene leukemia (AML), dispersivity large B cell lymphoid tumor (DLBCL) and multiple myeloma (MM)).But other Targeted cancer therapy agent (such as kinase inhibitor) also can combinationally use with the compounds of this invention.
2. preparation as an alternative
Theme of the present invention also can be called as follows:
The object needed to there being this uses the method for the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) of significant quantity as hereinbefore defined.
By the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) as hereinbefore defined to the subject effective amounts having this to need to treat the method for the disease being selected from disease disclosed herein.
Be used for the treatment of the method for PIM1-3 and/or FLT3 and/or DYRK1A relative disease, described method comprises the step to the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) as hereinbefore defined having the patient therapeuticallv of these needs to measure.
Be used for the treatment of the method for PIM1-3 and/or FLT3 and/or DYRK1A associated cancer, described method comprises the step to the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) as hereinbefore defined having the patient therapeuticallv of these needs to measure.
Be used for the treatment of the method for PIM1-3 and/or FLT3 and/or DYRK1A related inflammatory diseases, described method comprises the step to the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) as hereinbefore defined having the patient therapeuticallv of these needs to measure.
Be used for the treatment of the method for PIM1-3 and/or FLT3 and/or DYRK1A associated autoimmune disease, described method comprises the step to the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) as hereinbefore defined having the patient therapeuticallv of these needs to measure.
Be used for the treatment of the method for the neurodegenerative disease that PIM1-3 and/or FLT3 and/or DYRK1A is correlated with, described method comprises the step to the compound or pharmaceutically acceptable salt thereof according to formula (I) (comprising some preferred embodiments) as hereinbefore defined having the patient therapeuticallv of these needs to measure.
Hereinafter, the embodiment of embodiments more of the present invention is outlined.But described embodiment should not be interpreted as limiting the scope of the invention.
3. embodiment
3.1. the compound of embodiment 1:
The bromo-1-ethyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole hydrochloride (embodiment 1A):
By bromo-for 2,5,6-tri-1-ethyl-4-nitro-1H-1,3-benzodiazole (150mg, 0.35mmol) and BOC piperazine (260mg, 1.4mmol) are dissolved in EtOH (3.0ml).At 170 DEG C of temperature, gained mixture is stirred until completed (20 minutes) by LC/MS monitoring reaction under microwave condition.Mixture is made to be cooled to RT and to concentrate under vacuo.Use EA/ hexane (1: 1) at product purified on silica.Product be dissolved in Isosorbide-5-Nitrae-dioxane (3.0ml) and add the 4M HCl (1.0ml) in dioxane.At room temperature stir the mixture until completed (18 hours) by LC/MS monitoring reaction.Add ether (5.0ml), leach product, also dry with washed with diethylether, to obtain the bromo-1-ethyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole hydrochloride (41mg, 0.087mmol).
1H NMR(600MHz，DMSO)δ9.59(s，1H)，8.21(s，1H)，4.18(q，J＝7.2Hz，2H)，3.60-3.58(m，4H)，3.25(s，4H)，1.33(t，J＝7.2Hz，3H)；m/z 433.8；rt 2.4min.
Suitable raw material (SM) is used to prepare following compound by the method for embodiment 1A:
3.2. the compound of embodiment 2:
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole hydrochloride (embodiment 2A):
4-(the bromo-4-nitro of 5,6-bis--1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester (method 4A) (0.4mmol, 200mg) is dissolved in acetonitrile (5ml).Then, NaOH (0.5mmol, 19mg) is added.Under RT, mixture is stirred 0.5 hour.Then 2-iodopropane (32mmol, 538mg) is dropwise added.In sealed tube, gained mixture is stirred until completed (18 hours) by LC/MS monitoring reaction at 85 DEG C.Mixture is made to be cooled to RT and to concentrate under vacuo.Product to be dissolved in ethyl acetate and to wash with water.Make organic extract through MgSO 4dry, filter and concentrate.Use EA/ hexane (1: 4) at product purified on silica.Products therefrom (0.3mmol, 180mg) is dissolved in MeOH (3ml), then dropwise adds hydrogenchloride (4M in Isosorbide-5-Nitrae-dioxane, 1ml).Gained mixture is stirred under RT and spends the night.Filtering solids also uses Et 2o washs, to obtain the bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole hydrochloride (130mg).
1H NMR(600MHz，DMSO)δ9.37(s，2H)，8.28(s，1H)，4.62(hept，J＝6.9Hz，1H)，3.47-3.44(m，4H)，3.28-3.26(m，4H)，1.54(d，J＝6.9Hz，6H)；m/z 472；rt 2.4.
Suitable raw material is used to prepare following compound by the method for embodiment 2A.
3.3. the compound of embodiment 3:
(3R)-1-[the bromo-4-nitro-1H-1 of 1-(3-aminopropyl)-5,6-bis-, 3-benzodiazole-2-base] tetramethyleneimine-3-amine (embodiment 3A):
By 3-{2-[(3R)-3-amino-pyrrolidine-1-base]-5 at 0 DEG C, the bromo-4-nitro of 6-bis--1H-1,3-benzodiazole-1-base } propane-1-alcohol (53.2mg, MeOH/ triethylamine (7: 1v/v, 3.1mL) suspension 0.115mmol) stirs 10 minutes.The tert-Butyl dicarbonate (67.8mg, 0.264mmol) in MeOH (1.3mL) is slowly added under an argon atmosphere in 10 minutes.At 0 DEG C, mixture is stirred 1 hour, then at room temperature stirring 16 is little of completing (being detected by TLC, AcOEt-Hex:4-1).Under reduced pressure except desolventizing.By gained dissolution of solid in CH 2cl 2(4mL), and with water (3mL × 3) washing gained solution.Be separated organic layer, through anhydrous Na 2sO 4drying is also evaporated, to obtain N-[(3R)-1-[the bromo-1-of 5,6-bis-(3-hydroxypropyl)-4-nitro-1H-1, the 3-benzodiazole-2-base] pyrrolidin-3-yl] t-butyl carbamate (62.9mg as yellow solid, 0.108mmol, 97%).To be dissolved in the anhydrous tetrahydro furan (1.1mL) containing triphenylphosphine (32.3mg, 2.0mmol) and phthalic imidine (58.0mg, 2.0mmol) and to be further purified without the need to any.Dropwise add tetrahydrofuran (THF) (0.4mL) solution of diisopropyl azo-2-carboxylic acid (48 μ L, 2.2mmol), spend the night under at room temperature stirring.Therefore, remove desolventizing by evaporation and make residue dissolve in CH 2cl 2(4mL), through the solution washing of sodium bicarbonate and water, through dried over mgso, filtration be evaporated to drying.On a silica gel column chromatographic separation is carried out to residue, and with ethylacetate-hexane mixture (4: 1) wash-out, to obtain N-[(3R)-1-{5, the bromo-1-of 6-bis-[3-(1,3-dioxo-2,3-dihydro-1H-isoindole-2-base) propyl group]-4-nitro-1H-1,3-benzodiazole-2-base } pyrrolidin-3-yl] t-butyl carbamate (72.6mg, 0.102mmol, 99%).m/z＝693.0，rt＝3.7min。It is made to be suspended in dehydrated alcohol (1.0mL) solution also slowly adding hydrazine monohydrate (50.4 μ L, 1.017mmol) in dehydrated alcohol (3.0mL).Mixture is refluxed 2.0 hours.Evaporating solvent, obtains solid, adds ethanol (4.0mL) containing 4.4M HCl to make dissolution of solid in wherein.At room temperature stir the mixture until completed (18 hours) by LC-MS monitoring reaction.Add ether (5.0ml), leach product, with washed with diethylether, the dry preparation HPLC purifying that also passes through is to obtain (3R)-1-[1-(3-aminopropyl)-5, the bromo-4-nitro of 6-bis--1H-1,3-benzodiazole-2-base] tetramethyleneimine-3-amine.m/z 462.9；rt 1.8min.
Suitable raw material is used to prepare following compound by the method for embodiment 3A.
3.4. the compound of embodiment 4:
The bromo-4-nitro of 5-methyl-6--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole (embodiment 4A) and the bromo-6-methyl of 5--4-nitro-2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole (embodiment 4B):
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole (embodiment 2A) (0.08mmol, 50mg) is made to be suspended in Isosorbide-5-Nitrae-dioxane/H 2in the mixture (1.5ml) of O (10: 1).Add methyl-boron-dihydroxide (0.2mmol, 39.5mg) and Cs 2cO 3(0.16mmol, 34.5mg).With argon purge reaction mixture 5 minutes.Then, [1,1 '-bis-(diphenylphosphine) ferrocene] dichloro palladium (II) is added.Gained mixture is stirred until completed (16 hours) by LC/MS monitoring reaction at 130 DEG C.Make mixture be cooled to RT and pass through diatomite filtration.Vaporising under vacuum solvent.Product is dissolved in ethyl acetate and washes with water.Make organic extract through MgSO 4dry, filter and concentrate.Purified product on HPLC, to obtain the bromo-6-methyl of 5--4-nitro-2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole trifluoro-acetate (10mg).M/z 383.9; Rt 2.5; The bromo-4-nitro of 5-methyl-6--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole (5mg) m/z 383.9, rt 2.6;
1H NMR(300MHz，dmso)δ9.19(bs，2H)，8.13(s，1H)，4.59(sept，J＝6.9Hz，1H)，3.42-3.35(m，4H)，3.31-3.21(m，4H)，2.34(s，3H)，1.51(d，J＝6.9Hz，6H).
3.5. the compound of embodiment 8:
The bromo-1-ethyl of 5,6-bis--2-(piperazine-1-base)-1H-1,3-benzodiazole-4-carbonitrile hydrochloride (embodiment 8A):
Make 4-(5, the bromo-4-cyano group of 6-bis--1-ethyl-1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester (method 8A) (900mg, 2.18mmol) be dissolved in Isosorbide-5-Nitrae-dioxane (5.0ml) dioxane (2.0ml) also added containing 4M HCl.At room temperature stir the mixture until completed (18 hours) by LC/MS monitoring reaction.Add ether (10.0ml), leach product, also dry with washed with diethylether, to obtain the bromo-1-ethyl of 5,6-bis--2-(piperazine-1-base)-1H-1,3-benzodiazole-4-carbonitrile hydrochloride (820mg, 1.8mmol).
1H NMR(600MHz，DMSO)δ9.47(s，2H)，8.24(s，1H)，4.17(q，J＝7.2Hz，2H)，3.67-3.62(m，4H)，3.29(s，4H)，1.32(t，J＝7.2Hz，3H)，m/z 413.9；rt 2.2.
Suitable raw material is used to prepare following examples by the method for embodiment 8A.
3.6. the compound of embodiment 9:
The bromo-1-ethyl of 5,6-bis--2-(piperazine-1-base)-4-(trifluoromethyl)-1H-1,3-benzodiazole hydrochloride (embodiment 9A):
By 4-(5; the iodo-1H-1 of 6-bis-bromo-1-ethyl-4-; 3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester (150mg; 0.24mmol), 2; the fluoro-2-of 2-bis-(fluorosulfonyl) methyl acetate (0.092ml; 0.73mmol) be dissolved in DMF (3.0ml) with cupric iodide (I) (4.7mg, 0.024mmol).At 150 DEG C, gained mixture is stirred until completed (10 minutes) by LC/MS monitoring reaction under microwave condition.Mixture is made to be cooled to RT and to concentrate under vacuo.Residue to be dissolved in ethyl acetate and to wash with water.Make organic extract through MgSO 4drying, filters and concentrates.Use EA/ hexane (1: 1) at product purified on silica.Product is dissolved in Isosorbide-5-Nitrae-dioxane (1.0ml) dioxane (1.0ml) also added containing 4M HCl.At room temperature stir the mixture until completed (18 hours) by LC/MS monitoring reaction.By mixture concentrated under vacuo and on HPLC purifying, to obtain the bromo-1-ethyl of 5,6-bis--2-(piperazine-1-base)-4-(trifluoromethyl)-1H-1,3-benzodiazole hydrochloride (22mg, 0.05mmol).
1H NMR(600MHz，DMSO)δ9.21(bs，2H)，8.23(s，1H)，4.16(t，J＝7.2Hz，2H)，3.59-3.55(m，4H)，3.29(bs，4H)，1.31(t，J＝7.1Hz，3H)；m/z 456.8；rt 3.1.
Suitable raw material is used to prepare following examples by the method for embodiment 9A:
3.7. the compound of embodiment 21:
The bromo-1-cyclopropyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole trifluoro-acetate (embodiment 21A):
4-(bromo-1H-1, the 3-benzodiazole of 5,6-bis--2-base) piperazine-1-carboxylic acid tert-butyl ester (150mg, 0.33mmol) is dissolved in ethylene dichloride (5.0ml).Add cyclopropylboronic acid (56mg, 0.65mmol), venus crystals (II) (59mg, 0.33mol), 2,2 '-dipyridyl (51mg, 0.65mmol) and sodium carbonate (70mg, 0.65mmol).Gained mixture is stirred until completed (3 days) by LC/MS monitoring reaction at 60 DEG C.Mixture is made to be cooled to RT and to concentrate under vacuo.Product to be dissolved in DMC and to wash with water.Make organic extract through MgSO 4dry, filter and concentrate.Use EA/ hexane (1: 4) at product purified on silica.Product to be dissolved in sulfuric acid (dense) (2.0ml) and to stir 30 minutes at 0 DEG C, then disposable interpolation saltpetre (12mg, 0.12mmol) stir 3 hours again at 0 DEG C.Make reaction mixture naturally be warming up to room temperature and stir until reacted (16 hours).Mixture is poured in ice.Product is dissolved in DCM, through MgSO 4dry, filter and concentrate.Purified product on HPLC, to obtain the bromo-1-cyclopropyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole trifluoro-acetate (3.2mg, 0.007mmol); M/z 455.9; Rt 3min..
3.8. the compound of embodiment 22:
4-(the bromo-1-ethyl of 5,6-bis--4-nitro-1H-1,3-benzodiazole-2-base) piperazine-2-ketone (embodiment 22A):
By bromo-for 2,5,6-tri-1-ethyl-4-nitro-1H-1,3-benzodiazole (100mg, 0.23mmol) and 2-piperazinones (117mg, 1.17mmol) are dissolved in EtOH (3.0ml).At 170 DEG C of temperature, gained mixture is stirred until completed (20 minutes) by LC/MS monitoring reaction under microwave condition.Mixture is made to be cooled to RT and to concentrate under vacuo.Leach product, also dry with EtOH washing, to obtain (the bromo-1-ethyl of 5,6-bis--4-nitro-1H-1,3-benzodiazole-2-base) piperazine-2-ketone (97mg, 0.22mmol); M/z 462.9; Rt 3.1min..
Suitable raw material is used to prepare following examples by the method for embodiment 22A:
3.9. the compound of embodiment 26:
The bromo-4-nitro of 5,6-bis--2-(piperidin-4-yl)-1-(propane-2-base)-1H-1,3-benzodiazole (embodiment 26A):
By 4, the bromo-1-N-of 5-bis-(propane-2-base) benzene-1,2-diamines (2.8g, 9.1mmol) and hexahydroisonicotinic acid (isonipeconic acid) (1.17g, 9.1mmol) dissolve in phosphoric acid (17.82g, 0.18mol).At 180 DEG C, gained mixture is stirred 3.5 hours.Make mixture be cooled to RT and be diluted with water to 200ml.With solid NaOH by basified to pH 14.0.Then leach gained precipitate and use MeOH repeated washing.Concentrating filtrate under vacuo.Use DCM/MeOH/NH 3saturated MEOH (25: 15: 1) is at Al 2o 3(alkalescence) upper purified product.Products therefrom (8.7mmol, 3.9g) is dissolved in dense H 2sO 4(30ml) in.Then, on 0 DEG C, once property adds KNO 3(8.7mmol, 0.89g).At 0 DEG C, gained mixture is stirred 3 hours, and stir under RT and spend the night.Then, mixture is poured in ice.Filtration product also washes with water.Use DCM/MeOH/NH 3saturated MEOH (25: 15: 1) is at Al 2o 3(alkalescence) upper purified product, to obtain the bromo-4-nitro of 5,6-bis--2-(piperidin-4-yl)-1-(propane-2-base)-1H-1,3-benzodiazole (1.9g).
1H NMR(600MHz，DMSO)δ8.74(bs，1H)，8.48(s，1H)，8.35(bs，1H)，4.94(hept，J＝6.8Hz，1H)，3.52-3.46(m，1H)，3.42-3.37(m，2H)，3.08(bs，2H)，2.07-1.96(m，4H)，1.60(d，J＝6.9Hz，6H).m/z 446，8；rt 2，7min.
Suitable raw material is used to prepare following compound by the method for embodiment 26A.
3.10. the compound of embodiment 27:
The bromo-4-nitro of 5,6-bis--2-(piperidin-4-yl)-1-(piperidin-4-ylmethyl)-1H-1,3-benzodiazole (27A):
By 4-[5, the bromo-1-of 6-bis-({ 1-[(tert.-butoxy) carbonyl] piperidin-4-yl } methyl)-1H-1,3-benzodiazole-2-base] piperidines-1-carboxylic acid tert-butyl ester (method 16A) (0.04mmol, 20mg) is dissolved in dense H 2sO 4(1ml) in.Then, on 0 DEG C, once property adds KNO 3(0.07mmol, 6.6mg), stirs 3 hours by gained mixture at 0 DEG C, and stirs under RT and spend the night.Mixture is poured in ice.Purified product on preparation HPLC, to obtain compound 5,6-bis-bromo-4-nitro-2-(piperidin-4-yl)-1-(piperidin-4-ylmethyl)-1H-1,3-benzodiazole trifluoro-acetate (10mg); M/z 502.0; Rt 1,9min..
3.11. for the preparation of the method according to the compounds of this invention
3.11.1. method 1:
Bromo-1H-1, the 3-benzodiazole of 2,5,6-tri-:
Bromo-for 2-1H-1,3-benzodiazole (170mmol, 33.5g) is suspended in acetonitrile (400ml).Then, the acetonitrile (300ml) containing NBS (357mmol, 63.55g) is added.Gained mixture is stirred until completed (24 hours) by LC/MS monitoring reaction under RT.Filtration product also uses acetonitrile wash.Use EA/ hexane (1: 4) at product purified on silica, to obtain bromo-1H-1, the 3-benzodiazole (56g) of compound 2,5,6-tri-.
1H NMR(600MHz，DMSO)δ7.95(s，1H).；m/z 356.7；rt 3.0min.
3.11.2. method 2A:
The bromo-4-nitro of 2,5,6-tri--1H-1,3-benzodiazole:
Bromo-for 2,5,6-tri-1H-1,3-benzodiazole (method 1) (1.4mmol, 500mg) is dissolved in dense H 2sO 4(4ml) in.Then, on 0 DEG C, once property adds KNO 3(1.7mmol, 171mg).At 0 DEG C, gained mixture is stirred 3 hours, and stir under RT and spend the night.Mixture is poured in ice.Filtration product also washes with water, to obtain the bromo-4-nitro-1H-1 of compound 2,5,6-tri-, 3-benzodiazole (487mg).
1H NMR(600MHz，DMSO)δ14.33(s，1H)，8.22(s，1H).；m/z 399.7；rt 3.0min.
Suitable raw material is used to prepare following compound by the method for method 2A:
3.11.3. method 3A:
The bromo-1-ethyl of 2,5,6-tri--4-nitro-1H-1,3-benzodiazole
By bromo-for 2,5,6-tri-4-nitro-1H-1,3-benzodiazole (method 2) (28mmol, 10g) is dissolved in acetonitrile (200ml), then adds NaOH (33.8mmol, 1.35g).At room temperature gained mixture is stirred 0.5 hour.Then, add 2-iodoethane (225mmol, 35.16g), and mixture is heated to 85 DEG C until completed (20 hours) by LC/MS monitoring reaction.Mixture is made to be cooled to RT and to concentrate under vacuo.Product to be dissolved in ethyl acetate and to wash with water.Make organic extract through MgSO 4dry, filter and concentrate.Use EA/ hexane (1: 1) at product purified on silica, to obtain compound 2,5,6-tri-bromo-1-ethyl-4-nitro-1H-1,3-benzodiazole (mg).
1H NMR(600MHz，DMSO)δ8.58(s，1H)，4.36(q，J＝7.2Hz，2H)，1.33(t，J＝7.2Hz，3H)；m/z 427.8；rt 3.5min.
Suitable raw material is used to prepare following compound by the method for method 3A:
3.11.4. method 4A:
4-(the bromo-4-nitro of 5,6-bis--1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester:
By bromo-for 2,5,6-tri-4-nitro-1H-1,3-benzodiazole (method 2A) (17.5mmol, 7g) is dissolved in the EtOH (30ml) containing N-Boc-piperazine (52.5mmol, 9.78g).Gained mixture is stirred until completed (8 hours) by LC/MS monitoring reaction at 120 DEG C.Mixture is made to be cooled to RT and to concentrate under vacuo.Use DCM/MeOH (99: 1) at product purified on silica to obtain 4-(the bromo-4-nitro of 5,6-bis--1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester (6g).m/z 405.8；rt 2.4min.
Suitable raw material is used to prepare following compound by the method for embodiment 4A:
3.11.5. method 5A:
1-(the bromo-4-nitro of 2,5,6-tri--1H-1,3-benzodiazole-1-base) propane-2-alcohol:
Bromo-for 1,2,4-tri-5-oil of mirbane (10mmol, 2.5g) is dissolved in THF (75ml).Add triethylamine (7.6mmol, 773mg) and amino-2-propyl alcohol (7.6mmol, 574mg).Gained mixture is stirred until completed (24 hours) by LC/MS monitoring reaction at 45 DEG C.Mixture is made to be cooled to RT and to concentrate under vacuo.Use EA/ hexane (1: 4) at product purified on silica.Products therefrom (1.5g, 4mmol) is made to be suspended in EtOH, AcOH and H 2in the mixture of O (2: 2: 1), then add iron filings (17mmol, 0.947mg).By mixture supersound process 5 hours.Use EA/ hexane (1: 1) at product purified on silica.Products therefrom is suspended in EtOH (30ml), and adds water H 2o (2ml).Then, disposable interpolation potassium ethyl xanthonate (3.8mmol, 608mg).Gained mixture is stirred until completed (24 hours) by LC/MS monitoring reaction at 85 DEG C.Make reaction be cooled to 60 DEG C, add H 2o (30ml), then adds H 2o/AcOH (2: 1).Make mixture be cooled to RT, filtering solids also uses H 2o washs.Products therefrom (2mmol, 740mg) is dissolved in MeOH (20ml).Make reaction mixture be cooled to 0 DEG C and add Hydrogen bromide (0.4ml), then adding bromine (8mmol, 1.3g).Gained mixture is stirred under RT and spends the night, then add Na 2sO 4.Then, MeOH is evaporated.Use DCM aqueous layer extracted.Use EA/ hexane (1: 1) at product purified on silica.Products therefrom (1mmol, 400mg) is dissolved in dense H 2sO 4(7ml) in.Then, on 0 DEG C, once property adds KNO 3(1.1mmol, 118mg).Gained mixture is stirred 3 hours at 0 DEG C, and stirs under RT and spend the night.Then, mixture is poured in ice.Filtration product also washes with water.Use DCM/MeOH (95: 5) at product purified on silica, to obtain the bromo-1-of 2,5,6-tri-(propane-2-alcohol)-4-nitro-1H-1,3-benzodiazole (200mg).m/z 457.7；rt 3.3.
Suitable raw material is used to prepare following compound by the method for method 5A:
3.11.6. method 7A:
4-(iodo-1H-1, the 3-benzodiazole of 5,6-bis-bromo-1-ethyl-4--2-base) piperazine-1-carboxylic acid tert-butyl ester:
4-(the bromo-1-ethyl of 5,6-bis--1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester (6mmol, 3g) is dissolved in anhydrous THF (20ml).Make gained mixture be cooled to-78 DEG C, then dropwise add magnesium chloride-2,2 at such a temperature, 6,6-tetramethyl piperidine lithium chloride complex compound.Gained mixture is stirred 2 hours at-78 DEG C.Make mixture be warming up to-20 DEG C and dropwise add 1M I 2tHF solution.Make mixture be warming up to RT and stir 1.5 hours.Reaction mixture is poured into ice/NH 4on the mixture of Cl, then add saturated Na 2sO 3.Be extracted with ethyl acetate aqueous mixture.Make organic extract through MgSO 4dry, filter and concentrate.Use EA/ hexane (1: 1) at product purified on silica, to obtain 4-(iodo-1H-1, the 3-benzodiazole of 5,6-bis-bromo-1-ethyl-4--2-base) piperazine-1-carboxylic acid tert-butyl ester (1.5g).m/z 614.8；rt 4.4min.
Suitable raw material is used to prepare following compound by the method for method 7A:
3.11.7. method 8A:
4-(the bromo-1-ethyl of 5,6-bis--4-cyano group-1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester:
4-(iodo-1H-1, the 3-benzodiazole of 5,6-bis-bromo-1-ethyl-4--2-base) piperazine-1-carboxylic acid tert-butyl ester (0.2mmol, 100mg) is dissolved in acetonitrile (1.5ml).Then cupric cyanide (I) is added.At 160 DEG C, reaction is carried out 25 minutes in microwave.Enriched mixture under vacuo.Make product dissolve in ethyl acetate and wash with water.Make organic extract through MgSO 4dry, filter and concentrate.Use EA/ hexane (1: 4) at product purified on silica, to obtain 4-(the bromo-1-ethyl of 5,6-bis--4-cyano group-1H-1,3-benzodiazole-2-base) piperazine-1-carboxylic acid tert-butyl ester (80mg).m/z 423.7；rt 3.3min.
Suitable raw material is used to prepare following compound by the method for method 8A
3.11.8. method 13:
The fluoro-4-nitro of the bromo-6-of 2,5-bis--1-(propane-2-base)-1H-1,3-benzodiazole:
The fluoro-1-of bromo-for 2,5-bis-6-(propane-2-base)-1H-1,3-benzodiazole (method 5B) (0.15mmol, 50mg) is dissolved in TFA (0.5ml).Then under RT, slowly HNO is added 3(2.9mmol, 0.12ml).Gained mixture is at room temperature stirred and spends the night.Product is poured in ice.Filtration product also washes with water, to obtain the bromo-4-nitro-1H-1 of compound 2,5,6-tri-, 3-benzodiazole (487mg).
1H NMR(600MHz，DMSO)δ14.33(s，1H)，8.22(s，1H).；m/z 381；rt 3.4.
3.11.9. method 14A:
Bromo-5,6-bis-chloro-1H-1, the 3-benzodiazoles of 2-:
By chloro-for 5,6-bis-2,3-dihydro-1H-1,3-benzodiazole-2-thioketones (2mmol, 438mg) is dissolved in MeOH (20ml).Reaction mixture is cooled to 0 DEG C, and adds Hydrogen bromide (0.4ml), then add bromine (8mmol, 1.3g).Gained mixture is stirred under RT and spends the night, then add Na 2sO 4.Then, MeOH is evaporated.Use DCM aqueous layer extracted.Use EA/ hexane (1: 1) at product purified on silica, to obtain yellow solid (1mmol, 260mg), m/z 266.7; Rt 2.8min.
3.11.10. method 15A:
Bromo-for 1,2,4-tri-5-oil of mirbane (14mmol, 5g) is dissolved in i-PrOH (130ml).Add triethylamine (15.3mmol, 1.55g) and 2-aminopropane (15.3mmol, 0.91g).Gained mixture is stirred until completed (24 hours) by LC/MS monitoring reaction at 90 DEG C.Mixture is made to be cooled to RT and to concentrate under vacuo.Use EA/ hexane (1: 4) at product purified on silica.Products therefrom (3.33g, 9.85mol) is made to be suspended in EtOH, AcOH and H 2in the mixture of O (2: 2: 1), then add iron filings (49.3mmol, 2.75g).By mixture supersound process 5 hours.Use EA/ hexane (1: 1) at product purified on silica.Yield (2.8g) m/z 308, rt.3,2min..
3.11.11. method 16A:
4-[the bromo-1-of 5,6-bis-({ 1-[(tert.-butoxy) carbonyl] piperidin-4-yl } methyl)-1H-1,3-benzodiazole-2-base] piperidines-1-carboxylic acid tert-butyl ester (16A):
By 4,5-dibromobenzene-1,2-diamines (100mg, 0.38mmol) and 4-formylpiperidine-1-carboxylic acid tert-butyl ester (160mg, 0.76mmol) 2, stir 1 hour in 2,2 trifluoroethanols.Then evaporating solvent, and use EA/ hexane (1/1) at product purified on silica.Yield: 20mg.m/z 657，1，rt.4，2min.
3.11.12. method 17A:
(3S)-3-(bromo-1H-1, the 3-benzodiazole of 2,5,6-tri--1-base) tetramethyleneimine-1-carboxylic acid tert-butyl ester (17A):
Bromo-for 1,2,4-tri-5-oil of mirbane (4.4mmol, 1,6g) is dissolved in THF (75ml).Add triethylamine (7.6mmol, 773mg) and (3S)-3-amino-pyrrolidine-1-carboxylic acid tert-butyl ester (4.4mmol, 828mg).Gained mixture is stirred until completed (72 hours) by LC/MS monitoring reaction at 100 DEG C.Make mixture be cooled to RT, concentrate under vacuo.Use EA/ hexane (1: 4) at product purified on silica.Products therefrom (1.86g, 4mmol) is made to be suspended in EtOH, AcOH and H 2in the mixture of O (2: 2: 1), then add iron filings (17mmol, 0.947mg).By mixture supersound process 5 hours.Use EA/ hexane (1: 1) at product purified on silica.Make products therefrom be suspended in EtOH (30ml), add H 2o (2ml).Then, disposable interpolation potassium ethyl xanthonate (3.8mmol, 608mg).Gained mixture is stirred until completed (24 hours) by LC/MS monitoring reaction at 85 DEG C.Make reaction be cooled to 60 DEG C, add H 2o (30ml), then adds H 2o/AcOH (2: 1).Make mixture be cooled to RT, filtering solids also uses H 2o washs.Products therefrom (2mmol, 954mg) is dissolved in MeOH (20ml).Make reaction mixture be cooled to 0 DEG C, and add Hydrogen bromide (0.4ml), then add bromine (8mmol, 1.3g).Gained mixture is stirred under RT and spends the night, then add Na 2sO 4.Then, MeOH is evaporated.Use DCM aqueous layer extracted.Use EA/ hexane (1: 1) at product purified on silica.Yield 200mg, m/z:523,8, rt:3,2min..
3.12. the mensuration of vitro inhibition activity
Test the compounds of this invention is for the inhibit activities of Pim-1, Pim-2, Pim-3, Flt3wt, Flt3ITD, CDK2/E and DYRK1.Adopt the ADP-Glo from Promega Corporation (Madison, WI, USA) tMkinase assay carries out the test of compound.Determine the percent inhibition of 1 μM of concentration compound, result is shown in table 1A.
ADP-Glo tMkinase assay is the luminous ADP detection assay method by quantitatively measuring kinase activity to the amount of the ADP produced during kinase reaction.At kinase assay buffer (5mMMOPS, pH 7.5,5mM MgCl 2, 0.4mMEDTA, 1.5mMDTT) in carry out kinase assays.Use mensuration damping fluid that the 10mM sample be dissolved at first in DMSO is diluted to 1000nM.The substrate mixture in 30 μ L volume/holes comprises ATP (the final ATP concentration in each kinase assays equals its apparent ATP Km).
Use the Pim-1 (Biocentrum, Krak ó w, Poland) of 3ng/ hole concentration and adopt 80 μMs of concentration peptide KKRNRTLTV (Lipopharm, poland) as substrate, the Km ATP of mensuration is 50 μMs.
Use the Pim-2 (Biocentrum, Krak ó w, Poland) of 120ng/ hole concentration and adopt 10 μMs of concentration peptide RSRHSSYPAGT (Lipopharm, poland) as substrate, the Km ATP of mensuration is 6 μMs.
Use the Pim-3 (Biocentrum, Krak ó w, Poland) of 80ng/ hole concentration and adopt 150 μMs of concentration peptide KKRNRTLTV (Lipopharm, poland) as substrate, the Km ATP of mensuration is 36.6 μMs.
Use the Flt3wt (Carna Bioscience, Kobe, Japan) of 75ng/ hole concentration and adopt 40 μMs of concentration peptide EAIYAAPFAKKK (Lipopharm, poland) as substrate, the Km ATP of mensuration is 65 μMs.
Use FLT3-ITD (hFL T3, C-terminal fragment, the amino acid R571-S993 of 70ng/ hole concentration; Production number: 0778-0000-1, Proqinase, Germany) and adopt 250 μMs of concentration peptide EAIYAAPFAKKK (Lipopharm, poland) as substrate, the Km ATP of mensuration is 70 μMs.
Use the CDK2/E (Millipore Billerica, MA, USA) of 20ng/ hole concentration and adopt 108 μMs of concentration peptide PKTPKKAKKL (Lipopharm, poland) as substrate, the Km ATP of mensuration is 130 μMs.
Use the DYRK1 (Milipore, Billerica, MA, USA) of 50ng/ hole concentration and adopt 36 μMs of concentration peptide KKISGRLSPIMTEQ (Lipopharm, poland) as substrate, the Km ATP of mensuration is 35 μMs.
Measure and carry out in two steps: first, after kinase reaction, add isopyknic ADP-Glo tMreagent is to stop kinase reaction and to exhaust remaining ATP.Secondly, add kinase assay reagent to be converted into by ADP ATP simultaneously and allow the ATP that employing luciferase/luciferin response measurement is newly synthesized.The luminous signal produced is proportional and relevant with kinase activity to the ADP concentration of generation.Microplate spectrophotometer (Synergy 2 multi-mode microtiter plate reader [BioTek]) is used to detect luminescence.By data normalization, and obtain suppression per-cent according to following formula:
% suppresses-suppresses per-cent
Lum cpdthe luminous value (RLU) of-compound
Lum pCthe luminous value (RLU) of-positive control
Table 1A: the vitro inhibition of the compounds of this invention is active
Based on the activity shown in vitro test, the compounds of this invention is useful PIM-kinase inhibitor, and reason is that it suppresses Pim-1 (when 1 μM of test > 50%) in high degree.Also Pim-2 and Pim-3 is suppressed quite in high degree according to compound of the present invention.Some compounds suppress Flt3wt, and other not shown inhibit activities for Flt3wt.The compounds of this invention can not suppress CDK2/E substantially, and the compounds of this invention demonstrates the great suppression effect for DYRK1.
Suitable vitro assay (standard test according to DiscoveRx Corporation is carried out) is also used to test the binding characteristic of selected compounds and FLT3 kinase mutants.Compound illustrates and being combined more by force of FLT3 kinases Analyses of major carcinogens in mainstream mutant, see table 1B.
Table 1B: compound 1A and 2A is for the binding activities of FLT wild-type and kinase mutants
Kd[nM] 1A 2A
FLT3wt 400 130
FLT3(ITD) 74 18
FLT3(D835H) 120 28
FLT3(D835Y) 46 15
3.13. the mensuration of growth inhibitory activity in cancerous cell line
Obtain following clone and use it for following listed mensuration:
-people bone marrow mononuclear cell Double phenotypic leukemia MV4-11 cell (there is Flt3-ITD sudden change);
-human muscle creatine kinase MOLM16 cell;
-human muscle creatine kinase MOLM13 cell (there is Flt3-ITD sudden change);
-people myelogenous leukemia KG-1 cell;
-human erythroleukemia cell HEL92 cell;
-people lymphoma mantle cell Jeko-1 cell;
-human hepatocellular carcinoma HepG2 cell; And
-human colon adenocarcinoma SW-480 cell.
Measure according to following scheme, the example of described scheme as MV4-11 cell be described:
Iscove ' s MDM substratum (substratum) containing 10% foetal calf serum (FCS) is used to be inoculated in each hole of 96 hole microwell plates (being manufactured by Corning Corp.) by 10,000 MV4-11 cells.On the same day, by dimethyl sulfoxide (DMSO) (DMSO), the DMSO solution of each test-compound prepared with 10mmol/L concentration is diluted to further the concentration (0.1 μm of ol/L, 0.5 μm of ol/L, 1 μm of ol/L, 2.5 μm of ol/L, 5 μm of ol/L and 10 μm ol/L) of expectation, and diluted solution is added in each hole.At 37 DEG C, in 5% carbonic acid gas, each hole is cultivated 72 hours further.After this is hatched, according to the specification sheets of manufacturers carry out standard MTS mensuration ( aQueous One Solution Cell Proliferation Assay, Promega).In brief, 10 μ l MTS (3-(4 are added to every hole, 5-dimethyl-2-thiazolyl)-5-(carboxy--methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, and at 37 DEG C, cultivate 2 hours in 5% carbonic acid gas.After this is hatched, microplate spectrophotometer (Synergy 2 multi-mode microtiter plate reader (Bio Tek)) is used to measure the absorbancy in each hole at 490nm place.The value of the cell of not hatching with test-compound is appointed as 100%.By by these values with compare being added with the absorbance difference obtained in the hole of each test-compound, the cell survival (% viability) of calculating after test-compound process.Result illustrates in table 2.
Table 2: the inhibit activities that the compounds of this invention grows neoplastic cell
If compounds exhibit goes out ED50 < 10 μMs, then think compound cell growth inhibiting efficiently.Mensuration shows effectively to suppress neoplastic cell growth in human carcinoma cell line as above according to compound of the present invention.
3.14. to the analysis of the Pim kinase biomarker thing in response to the cell with the compounds of this invention process
? mV4-11 cellin test compound 1A and 2Ato the kinase whose suppression effect of Pim (see above).With each compound treated cells 4 hours and 24 hours that concentration is 0.25 μM, 0.5 μM, 1 μM, 2.5 μMs and 5 μMs.Working concentration is the positive control Ref.A (commercially available inhibitor SGI-1776 [available from Selleck Bio]) of 5 μMs.By DMSO (dimethyl sulfoxide (DMSO)) as negative control.The level of following typical Pim-1 kinase biomarker thing is assessed: c-Myc, phosphorylation 4EBP1 (Ser65, Thr37 and 46) and phosphorylation S6 (Ser235).After process 4 hours and 24 hours, all with dosage-dependent manner, (in the test using compound 2A, under higher concentration and longer incubation time, pS6 phosphorylation improves the level of c-myc albumen, phosphorylation 4EBP1 and pS6 again; This effect is nonspecific and is for massive apoptosis, and it can identify from the PARP cutting be increased sharply) lower.In addition, have evaluated the level of short apoptosis and short viable biological mark.First, after compound stimulates 4 hours and 24 hours in higher concentrations, all observed the induction of apoptosis, this identifiable design be through the PARP albumen of cutting form appearance and express improve.Illustrate the analysis of short survivin Mcl-1, the dose-dependently protein after 4 hours and 24 hours is lowered.Tubulin levels is assessed as with reference to loading control.In addition, have evaluated phosphorylation p44/42 (Erk1/2) level as Flt3 biomarker; As drawn from Fig. 1 and Fig. 2, the level of phosphorylation p44/42 is also lower.
The result of compound 1A is shown in Figure 1, and the result of compound 2A is shown in Figure 2.
Compound 1BI is tested to the kinase whose suppression effect of Pim in MV4-11 cell.With the compound 1BI cell process 4 hours and 24 hours that concentration is 0.25 μM, 0.5 μM, 1 μM, 2.5 μMs and 5 μMs.Working concentration is positive control Ref.A (SGI-1776, see above) and the Ref.B (commercially available inhibitor Sutent (sunitinib) [available from Ark Pharm]) of 5 μMs.By DMSO (dimethyl sulfoxide (DMSO)) as negative control.The level of following typical Pim-1 kinase biomarker thing is assessed: c-myc, phosphorylation 4EBP1 (Ser65, Thr37 and 46) and phosphorylation S6 (Ser235/236).After process 4 hours and 24 hours, the level (Ser65, Thr37/46 of locating at higher concentrations and at 24 hours) of c-myc albumen and phosphorylation 4EBP1 is all lowered with dosage-dependent manner.After with all concentration process 4 hours and 24 hours, the level of phosphorylation S6 all almost reduces completely.In addition, have evaluated the level of short apoptosis and short viable biological mark.First, after stimulating 4 hours with the compound of maximum concentration, observe the induction of apoptosis, this show as through the PARP albumen of cutting form appearance and express improve.Illustrate the analysis of short survivin Mcl-1, the dose-dependently protein after 4 hours and 24 hours is lowered.Tubulin levels is evaluated as with reference to loading control.In addition, have evaluated phosphorylation p44/42 (Erk1/2) level as Flt3 biomarker; As drawn from Fig. 3, phosphorylation p44/42 level is also lower.
The result of compound 1BI is shown in Figure 3.
In MOLM-16 cell (acute myeloid leukemia cells in children system), also test compound 1BI to the kinase whose suppression effect of Pim.With the compound 1BI process cell 4 hours and 24 hours that concentration is 0.1 μM, 0.25 μM, 0.5 μM, 1 μM and 2.5 μMs.Working concentration is positive control Ref.A (SGI-1776, see above) and the Ref.B (Sutent, see above) of 5 μMs.By DMSO (dimethyl sulfoxide (DMSO)) as negative control.The level of following typical Pim-1 kinase biomarker thing is assessed: c-myc, phosphorylation 4EBP1 (Ser65, Thr37 and 46) and phosphorylation S6 (Ser235/236).After process 4 hours and 24 hours, the level of c-myc albumen and phosphorylation 4EBP1 (Ser65 and Thr37/46) is all lowered with dosage-dependent manner.After with all concentration process 4 hours and 24 hours, phosphorylation S6 level all almost reduces completely.Have evaluated the level of short apoptosis biomarker; Observe the induction of apoptosis, this show as through the PARP albumen of cutting form appearance and express improve.Tubulin levels is evaluated as with reference to loading control.
In MOLM-16 cell, the result of compound 1A is shown in Figure 4.
More than analyze and clearly illustrate that and can suppress PIM kinases in vivo according to compound of the present invention, reason is that downstream PIM kinase target indicates aobvious being affected.
3.15. for the mensuration of the activity in vivo of the xenograft tumours of implantation immunosuppressant animal
Several compounds of the present invention is have studied in murine xenogralt (for studying the factor participating in vicious transformation, Infiltration and metastasis, and for checking the in-vivo tumour heteroplastic transplantation model of the response to treatment).In order to accept the object of donor leukemia cell (MV4-11 or MOLM16 cell), use the mouse of immunocompromised host, that is, the immunodeficient mouse (NOD/scid, SCID/beige) be particularly badly damaged.When tumor size develops into about 50mm 3to 200mm 3time, the scheme of (QD) or every day twice (BID) according to once a day, compound 2 to 3 week of oral administration as shown in following table 3 and 3a every day.In experimentation, monitoring mouse also measures following two parameters: as Tumor growth inhibition (TGI) factor for the treatment of efficacy measures; As body weight change (Δ BW) factor that possible toxicity of compound is measured.Result is shown in table 3 and 3a.
Table 3:MV4-11 xenotransplantation result.TGI-Tumor growth inhibition, Δ BW-body weight change, QD-once a day, BID-every day twice.
In test-compound, compound 2A, 1AP and 1AX illustrate best antitumour activity, and wherein TGI is more than 97%.Compound 2D and 1BI illustrates the excellent TGI higher than 87%.Compound 1A, 1M, 1AH and 1AZ produce the Tumor growth inhibition higher than 70%, therefore can be classified as the compound with good effect.Compound 1N and 1R illustrate close to up to 70% the TGI of moderate.As by monitoring body weight change assessed, all test-compounds all do not produce serious toxicity.If observe and lose weight, and this alleviates more than 10%, so thinks that all compounds do not have toxicity.
In addition, enter in xenotransplantation in the MOLM16 cell of immunocompromised host mouse and test compound 2A and other embodiments.Provide one of obtained result below.As drawn from table 3a and Fig. 5, compound 2A process is used to cause the suppression > 99% of tumor growth.
Table 3a:MOLM16 xenotransplantation result.TGI-Tumor growth inhibition, Δ BW-body weight change, QD-once a day.
Then, in the xenotransplantation research of acute myeloid leukaemia (MV-4-11), have evaluated compound 26A, it in vivo separately or (show 3b with cytosine arabinoside combined treatment; Fig. 6).The compound 26A tested with two kinds of dosage (50mg/kg and 25mg/kg) and using with every day twice (BID); Cytosine arabinoside is used, a Wednesday time (TIW) with the dosage of 50mg/kg.During 15 days of compound administration, show the dose-dependently antitumour activity of compound 26A (using separately).Tumor growth inhibition reaches-82% and-77% respectively.In addition, with cytosine arabinoside combined treatment, synergistic effect is shown, it depends on dosage similarly, and causes the TGI of-99% and-89%.The intermediate tumor growth-inhibiting of-60% is only caused with cytosine arabinoside process.
Table 3b:MV-4-11 xenotransplantation result.TGI-Tumor growth inhibition, Δ BW-body weight change, BID-is secondary on every Wendesdays for every day twice, TIW-.
3.16. interact with the collaborative of carcinostatic agent or be added
Being combined in measure the compounds of this invention and commercially available carcinostatic agent the effect that growth of cancer cells suppresses, compound 1A and 26A and carcinostatic agent being combined and is added into cell, as shown in table 4.Carcinostatic agent also illustrates in table 4.
Described be combined in fixed concentration under study, wherein test under two constant densities compound 1A or compound 26A-mono-correspond to ED50 value (for the compound 1A in specific cells system (namely for HEL-92:5.46 μM; U-937:6.64 μM; MV4-11:0.50 μM; PC3:2.91 μM; Mino:1.7 μM); For compound 26A:0.1 μM in MV4-11; MOLM-16:0.4 μM), one lower than ED50 value, as low twice (see table 4), the therapeutical agent simultaneously shown in six progressive concentration (table 4) scope build-in test tables 4.With the combination incubated cell 72 hours of compound.After described hatching, carry out cell survival mensuration (CellTiter according to the specification sheets of manufacturers water-based determination of non-radioactive cell proliferation (AQueous Non-RadioactiveCell Proliferation Assay), Promega).Result is expressed as compared with the cell using supporting agent (DMSO) to process, the per-cent of viable cell after using independent medicine or combined treatment.
Based on these data, CompuSyn software (ComboSyn SoftwareIncorporated, Paramus, NJ) is used to measure combinatorial index (CI) value.In order to show combined effect, adopt following criterion: CI value < 1 shows to work in coordination with, CI value=1 shows summation action, and CI value > 1 shows antagonistic action.
Table 4. combination research-embodiment 1A and 26A.
Above result shows that the compounds of this invention is suppressing to work synergistically or additively in the Growth of Cells in the cancerous cell line tested (C: cytosine arabinoside with the target anticancer inhibitor of the carcinostatic agent determined or PI3K/Akt/mTOR or Jak/STAT approach; V:Vosaroxin).
3.17. to the mensuration that the possibility of hERG is active
HERG (people ether-à-go-go-genes involved) passage is the important anti-target of potential new drug, and reason is that its suppression can cause sudden death.In order to determine whether the compounds of this invention works to hERG, tests as follows.
At room temperature use QPatch (Sophion Bioscience A/S, Denmark, Automated parallel Patch Clamp System) carrys out the hERG potassium channel current (I of the compounds for mammalian cells shown in evaluation form 5 krsurrogate, acute activation, delayed rectification cardiac potassium electric current) interaction in vitro.At each compound shown in 0.1 μM, 1 μM, 3 μMs, 10 μMs and 30 μMs of lower evaluation forms 5, the wherein each concentration of test in minimum two cells (n >=2).The time length being exposed to each compound concentration is 3 minutes.Being summarised in shown in table 5 of result.Positive control (E-4031) confirms test macro suppresses (suppression of under 0.5 μM 98.6%) susceptibility to hERG.Usually, think that the compound of display IC50 > about 0.5 μM is inoperative to hERG, therefore think safe.
HERG IC50 during table 5. automatization patch clamp measures measures
As what can draw from the result as described in table 5, the compounds of this invention substantially can not target hERG, therefore can think to suppress relevant sudden death risk to be safe for hERG.
3.18. to the mensuration that the possibility of CYP is active
Usually, medicine should preferably not T suppression cell cytochrome p 450 enzyme, can not affect adversely to make bio-transformation.Therefore, the compounds of this invention is measured to the activity of this fermentoid (CYP).
Cytochrome P450 suppresses to measure and is conducive to identifying medicine and the lower drug candidate (weak enzyme inhibitors) of drug interaction possibility.Carry out in vitro testing to determine whether medicine suppresses specific CYP enzyme.Experiment comprises hatches medicine together with the probe substrate of CYP enzyme, wherein adopts following reconstitution cell cytochrome p 450 isoform and can carry out the multiple probe substrate of fluoroscopic examination: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.The program uses close to apparent K msingle concentration of substrate and multiple compound concentration.By IC 50be defined as wherein enzymatic activity and 50% point suppressed occurs.
Measure in 96 hole microwell plates.Row is appointed as A to H, and row are appointed as 1 to 12.Carry out specific experimental design to measure IC in two row in 12 holes 50.Each compound (test-compound see table 6) is added into the hole of row 1, and serial dilution is to the hole of row 8.Hole 9 and 10 is not containing the control wells (signal of suppression therefore not detected completely) of test-compound.Enzyme/end mixture (only signal existing in this some holes is background noise), in blank, wherein after add STOP solution in NADPH regeneration system rapidly, is added in the hole of row 11 and 12.Measure with 0.2ml final volume/hole.
Under 10mM concentration, in DMSO, prepare the liquid storage of test-compound.The liquid storage of all compounds (tested with contrast) is prepared as in mensuration 500 times that expect concentration, dilutes 500 times with buffered soln A.Use the compound of following 8 concentration to carry out IC 50measure: 0.009 μM, 0.027 μM, 0.082 μM, 0.247 μM, 0.741 μM, 2.22 μMs, 6.67 μMs and 20 μMs.Making after compound mixes with containing the solution of NADPH-cofactor, by mixed plate preincubate at least 10 minutes in the incubator of 37 DEG C; Then, use the excitation/emission spectral filter recommended to measure the fluorescence of compound, thus eliminate the error result deriving from the autofluorescence of compound.In following steps, enzyme/substrate mixture is added into row 1 to 10 and plate is hatched at 37 DEG C the concrete time (incubation time is 30 minutes to 45 minutes) depended on CYP and test.STOP SOLUTION is added into porose and after respective enzyme/substrate mixture being added into the hole of row 11 and 12, with fluorescent plate scanner scanning plate.The excitation/emission spectral filter for particular assay is described in GenTest screening reagent box working instructions.IC is calculated from fluorescence data by linear interpolation 50, wherein use following classification: high inhibition < 1.1 μMs; Medium suppression: 1.1 μMs to 3.3 μMs; Slight suppression: 3.3 μMs to 10 μMs; Weak suppression: > 10 μMs.
Table 6:CYP 3A4 the selection result
Embodiment CYP suppresses
1D Weak
1A Slightly
2A Slightly
1Q Slightly
2H Slightly
1AA Medium
1AE Medium
1AF Weak
1AH Weak
22G Weak
2I Slightly
1AS Slightly
1AX Medium
22I Weak
22J Slightly
1BH Weak
1BI Medium
1BK Weak
1BC Slightly
1BD Weak
22AB Slightly
1BM Medium
26A Weak
1M Medium
2D Medium
1AH Medium
Result shown in table 6 shows that the compounds of this invention is weak CYP inhibitor.
Certain preferred embodiments of the present invention relates to:
1. formula (I) compound or pharmaceutically acceptable salt thereof:
Wherein
X 1be selected from nitro, cyano group, methyl, trifluoromethyl ,-C (=O) T 1,-C (=O) OT 4with-S (=O) 2t 4;
Z and X 2be selected from F, Cl, Br, I ,-C independently of one another 1-3alkyl and trifluoromethyl, prerequisite is Z and X 2be asynchronously-C 1-3alkyl;
X 3be selected from H ,-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F, OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 3 to 6 yuan of saturated carbon rings or heterocycle replaced, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced;
X 4do not exist, or be selected from-NR 4-and-N (R 4) (CH 2)-;
R 4be selected from H and-C 1-6alkyl;
Y 1be selected from H ,-C 1-6alkyl and 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is, if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, wherein said-C 1-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 5 to 6 yuan of saturated heterocyclics replaced, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7, N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced;
T 1, T 2and T 3be selected from H and-C independently of one another 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 7,-S (=O) 2oT 8with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 4-C 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-CO (=O) N (T 5) (T 6) ,-S (=O) 2t 8,-S (=O) 2oT 7with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 5, T 6and T 7be selected from H and-C independently of one another 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced; And
T 8be selected from-C 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced.
2. the compound according to 1, wherein Z and X 2be selected from F, Cl, Br, I and trifluoromethyl independently of one another.
3. the compound according to 1 or 2, wherein X 3be selected from-C 2-6alkyl ,-C 2-6thiazolinyl ,-C 2-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 2-6alkyl ,-C 2-6thiazolinyl and-C 2-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 3 to 6 yuan of saturated carbon rings or heterocycle replaced, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1, N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
4. the compound according to 1 or 2, wherein X 3be selected from H ,-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl, wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
5. the compound according to 1 or 2, wherein X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl by 3 to 6 yuan of carbocyclic rings or heterocycle replace, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
6. the compound according to any one of 1 to 5, wherein X 4-NR 4-, and Y 1be selected from H and-C 1-6alkyl, wherein said-C 1-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
7. the compound according to any one of 1 to 5, wherein Y 1be 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
8. the compound according to 7, wherein Y 1be 4 to 7 yuan of saturated carbon rings or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
9. the compound according to 7 or 8, wherein X 4do not exist.
10. the compound according to 1, wherein said compound is selected from:
The bromo-1-ethyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole;
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole;
2-[(3R)-3-amino-pyrrolidine-1-base]-5,6-bis-bromo-1-(propane-2-base)-1H-1,3-benzodiazole-4-formonitrile HCN;
Bromo-1-ethyl-1, the 3-benzodiazole-4-formonitrile HCN of 2-[(3R)-3-amino-pyrrolidine-1-base]-5,6-bis-;
The bromo-2-of 5,6-bis-[(2S)-2-methylpiperazine-1-yl]-4-nitro-1-(propane-2-base)-1H-1,3-benzodiazole;
Anti-form-1-N-[the bromo-4-nitro of 5,6-bis--1-(propane-2-base)-1H-1,3-benzodiazole-2-base] hexanaphthene-Isosorbide-5-Nitrae-diamines;
The bromo-1-cyclopentyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole hydrochloride;
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-propyl group-1H-1,3-benzodiazole;
The bromo-1-of 5,6-bis-(2-methyl-propyl)-4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole;
The bromo-1-of 5,6-bis-(Cvclopropvlmethvl)-4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole;
(3S)-1-(the bromo-1-ethyl of 5,6-bis--4-nitro-1H-1,3-benzodiazole-2-base) piperidines-3-amine;
(3S)-1-[the bromo-4-nitro of 5,6-bis--1-(propane-2-base)-1H-1,3-benzodiazole-2-base] piperidines-3-amine;
(3S)-1-[the bromo-4-nitro of 5,6-bis--1-(propane-2-base)-1H-1,3-benzodiazole-2-base] tetramethyleneimine-3-amine;
(3R)-1-[the bromo-4-nitro of 5,6-bis--1-(propane-2-base)-1H-1,3-benzodiazole-2-base] tetramethyleneimine-3-amine;
The bromo-4-nitro of 5,6-bis--1-(propane-2-base)-N-[(3S)-pyrrolidin-3-yl]-1H-1,3-benzodiazole-2-amine hydrochlorate;
Bromo-1-ethyl-1, the 3-benzodiazole-4-carbonitrile hydrochloride of 2-[(3S)-3-amino piperidine-1-base]-5,6-bis-;
The bromo-4-nitro of 5,6-bis--N-[(3S)-piperidines-3-base]-1-(propane-2-base)-1H-1,3-benzodiazole-2-amine hydrochlorate; And
The bromo-1-of 5,6-bis-(2-methyl-propyl)-4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole hydrochloride.
11. compounds according to any one of 1 to 10, wherein said pharmacologically acceptable salt is selected from: hydrochloride, hydrobromate, hydriodate, nitrate, vitriol, hydrosulfate, phosphoric acid salt, acid phosphate, γ-picolinic acid salt, acetate, lactic acid salt, salicylate, Citrate trianion, tartrate, pantothenate, bitartrate, ascorbate salt, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutaminate, mesylate, esilate, benzene sulfonate, tosilate and pamoate.
12. pharmaceutical compositions, it comprises the compound according to any one of 1 to 11.
13. pharmaceutical compositions according to 12, it is used for the treatment of and is selected from following disease: cancer, autoimmune disease and inflammatory diseases.
14. pharmaceutical compositions according to 12 or 13, it is used for the treatment of and is selected from following disease: the leukemia comprising Acute Lymphoblastic Leukemia, acute myelogene leukemia and chronic lymphocytic leukemia, lymphoma, myelomatosis, myeloproliferative disease, allograft rejection, inflammatory bowel, multiple sclerosis, psoriatic, rheumatoid arthritis, systemic lupus erythematous, alzheimer's disease and mongolism.
15. for regulating or adjusting and preferably suppress the method for serine/threonine or Tyrosylprotein kinase, described kinases is preferably selected from PIM1-3, FLT3 and DYRK1A, and be more preferably selected from PIM1-3 and DYRK1A, wherein make described serine/threonine or Tyrosylprotein kinase be exposed to the formula of at least one according to any one of 1 to 11 (I) compound, wherein said method is preferably carried out outside human or animal's health.
16. formula (I) compounds according to any one of 1 to 11 are used as serine/threonine or tyrosine kinase modulators and the purposes of preferred inhibitor, wherein said kinases is preferably selected from PIM1-3, FLT3 and DYRK1A, and is more preferably selected from PIM1-3 and DYRK1A.

Claims (16)

1. formula (I) compound or pharmaceutically acceptable salt thereof:
Wherein
X 1be selected from nitro, cyano group, methyl, trifluoromethyl ,-C (=O) T 1,-C (=O) OT 4with-S (=O) 2t 4;
Z and X 2be selected from F, Cl, Br, I ,-C independently of one another 1-3alkyl and trifluoromethyl, prerequisite is Z and X 2be asynchronously-C 1-3alkyl;
X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl and 3 to 6 yuan of saturated carbon rings or heterocycle, prerequisite is the tie point on described heterocycle is carbon, and wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced, and wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 3 to 6 yuan of saturated carbon rings or heterocycle replaced, wherein said 3 to 6 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced;
X 4do not exist, or be selected from-NR 4-and-N (R 4) (CH 2)-;
R 4be selected from H and-C 1-6alkyl;
Y 1be selected from H ,-C 1-6alkyl and 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is, if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, wherein said-C 1-6alkyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3) and one or more substituting group of 5 to 6 yuan of saturated heterocyclics replaced, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced;
T 1, T 2and T 3be selected from H and-C independently of one another 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 7,-S (=O) 2oT 8with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 4-C 1-6alkyl, described-C 1-6alkyl is optionally independently selected from F ,-N (T 5) (T 6) ,-OT 7,-ST 7, cyano group ,-C (=O) OT 7,-C (=O) N (T 5) (T 6) ,-OC (=O) N (T 5) (T 6) ,-S (=O) 2t 8,-S (=O) 2oT 7with-S (=O) 2n (T 5) (T 6) one or more substituting group replaced;
T 5, T 6and T 7be selected from H and-C independently of one another 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced; And
T 8be selected from-C 1-6alkyl, described-C 1-6one or more substituting group that alkyl is optionally independently selected from F, amino, hydroxyl, sulfydryl and cyano group replaced.
2. compound according to claim 1, wherein X 1be selected from nitro, cyano group, trifluoromethyl ,-C (=O) T 1with-S (=O) 2t 4.
3. compound according to claim 1 and 2, wherein Z and X 2be selected from F, Cl, Br, I and trifluoromethyl independently of one another.
4. compound according to any one of claim 1 to 3, wherein X 3be selected from-C 1-6alkyl ,-C 1-6thiazolinyl ,-C 1-6alkynyl, wherein said-C 1-6alkyl ,-C 1-6thiazolinyl and-C 1-6alkynyl is optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1with-S (=O) 2n (T 2) (T 3) one or more substituting group replaced.
5. compound according to any one of claim 1 to 4, wherein X 3-C 1-6alkyl, is preferably-C 1-3alkyl or-C 1-2alkyl.
6. compound according to any one of claim 1 to 5, wherein Y 1be 4 to 7 yuan of saturated or unsaturated aromatic carbocyclic or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
7. compound according to claim 6, wherein Y 1be 4 to 7 yuan of saturated carbon rings or heterocycle, prerequisite is if X 4-NR 4-or-N (R 4) (CH 2the tie point of)-, then on described heterocycle is carbon, and wherein said 4 to 7 yuan of carbocyclic rings or heterocycle are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced, wherein said-C 1-3alkyl is optionally independently selected from-OT 7,-N (T 2) (T 3) and one or more substituting group of 6 yuan of saturated heterocyclics replaced.
8. the compound according to claim 6 or 7, wherein X 4do not exist.
9. compound according to any one of claim 1 to 5, wherein X 4do not exist, and Y 1be 6 yuan of saturated heterocyclics, wherein said 6 yuan of heterocycles are optionally independently selected from F ,-OT 1,-N (T 2) (T 3) ,-C (=O) N (T 2) (T 3) ,-C (=O) OT 1,-ST 1,-S (=O) 2t 1,-S (=O) 2n (T 2) (T 3), oxo and-C 1-3one or more substituting group of alkyl replaced.
10. compound according to claim 1, wherein said compound is selected from:
The bromo-1-ethyl of 5,6-bis--4-nitro-2-(piperazine-1-base)-1H-1,3-benzodiazole;
The bromo-4-nitro of 5,6-bis--2-(piperazine-1-base)-1-(propane-2-base)-1H-1,3-benzodiazole;
(3S)-1-(the bromo-1-ethyl of 5,6-bis--4-nitro-1H-1,3-benzodiazole-2-base) piperidines-3-amine;
The bromo-2-of 5,6-bis-[(2S)-2-methylpiperazine-1-yl]-4-nitro-1-(propane-2-base)-1H-1,3-benzodiazole; And
The bromo-4-nitro of 5,6-bis--2-(piperidin-4-yl)-1-(propane-2-base)-1H-1,3-benzodiazole.
11. according to compound in any one of the preceding claims wherein, wherein said pharmacologically acceptable salt is selected from: hydrochloride, hydrobromate, hydriodate, nitrate, vitriol, hydrosulfate, phosphoric acid salt, acid phosphate, γ-picolinic acid salt, acetate, lactic acid salt, salicylate, Citrate trianion, tartrate, pantothenate, bitartrate, ascorbate salt, succinate, maleate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutaminate, mesylate, esilate, benzene sulfonate, tosilate and pamoate.
12. pharmaceutical compositions, it comprises according to compound in any one of the preceding claims wherein.
13. pharmaceutical compositions according to claim 12, it is used for the treatment of and is selected from following disease: cancer, autoimmune disease and inflammatory diseases.
14. pharmaceutical compositions according to claim 12 or 13, it is used for the treatment of and is selected from following disease: leukemia, comprises Acute Lymphoblastic Leukemia, acute myeloid leukaemia and chronic lymphocytic leukemia; Lymphoma, comprises dispersivity large B cell lymphoid tumor; Myelomatosis, comprises multiple myeloma; Myeloproliferative disease; Allograft rejection; Inflammatory bowel; Multiple sclerosis; Psoriatic; Rheumatoid arthritis; Systemic lupus erythematous; Alzheimer's disease and mongolism.
15. for regulating or adjusting and preferably suppress the method for serine/threonine or Tyrosylprotein kinase, described kinases is preferably selected from PIM1-3, FLT3 and DYRK1A, and be more preferably selected from PIM1-3 and DYRK1A, wherein make described serine/threonine or Tyrosylprotein kinase be exposed to the formula of at least one according to any one of claim 1 to 11 (I) compound, wherein said method is preferably carried out outside human or animal's health.
16. formula (I) compounds according to any one of claim 1 to 11 are as serine/threonine or tyrosine kinase modulators and the purposes of preferred inhibitor, wherein said kinases is preferably selected from PIM1-3, FLT3 and DYRK1A, and be more preferably selected from PIM1-3 and DYRK1A or be selected from PIM1-3 and FLT3, described FLT3 comprises FLT3 wild type kinase and FLT3 saltant type kinases.
CN201380067040.1A 2012-12-21 2013-12-20 Benzimidizole derivatives as kinase inhibitor Active CN104936951B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223265.8A GB201223265D0 (en) 2012-12-21 2012-12-21 Novel benzimidazole derivatives as kinase inhibitors
GB1223265.8 2012-12-21
PCT/EP2013/077754 WO2014096388A2 (en) 2012-12-21 2013-12-20 Novel benzimidazole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN104936951A true CN104936951A (en) 2015-09-23
CN104936951B CN104936951B (en) 2018-02-06

Family

ID=47682482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067040.1A Active CN104936951B (en) 2012-12-21 2013-12-20 Benzimidizole derivatives as kinase inhibitor

Country Status (22)

Country Link
US (2) US9388192B2 (en)
EP (1) EP2935244B1 (en)
JP (1) JP6169185B2 (en)
KR (1) KR101779272B1 (en)
CN (1) CN104936951B (en)
AU (1) AU2013366513B2 (en)
BR (1) BR112015014701B8 (en)
CA (1) CA2896156C (en)
CY (1) CY1120692T1 (en)
DK (1) DK2935244T3 (en)
ES (1) ES2688395T3 (en)
GB (1) GB201223265D0 (en)
HR (1) HRP20181429T8 (en)
HU (1) HUE039376T2 (en)
IL (1) IL239193A0 (en)
LT (1) LT2935244T (en)
MX (1) MX369589B (en)
PL (1) PL2935244T3 (en)
PT (1) PT2935244T (en)
RS (1) RS57658B1 (en)
SI (1) SI2935244T1 (en)
WO (1) WO2014096388A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491691A (en) * 2020-04-02 2021-10-12 深圳贝瑞生物医药科技有限公司 Compound for preparing antitumor drugs or 14-3-3 eta protein inhibitors
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
MY182908A (en) 2014-01-14 2021-02-05 Millennium Pharm Inc Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP6896619B2 (en) 2014-10-06 2021-06-30 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Cystic fibrosis transmembrane conductance regulator modulator
EP3344039A4 (en) * 2015-09-03 2019-08-28 Arizona Board of Regents on behalf of the University of Arizona Small molecule inhibitors of dyrk1a and uses thereof
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN109803962B (en) 2016-09-30 2022-04-29 弗特克斯药品有限公司 Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions
IL294237A (en) 2016-12-09 2022-08-01 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US9855255B1 (en) 2017-05-26 2018-01-02 King Saud University Substituted naphthyridinyl hydrazines as anti-liver cancer agents
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
JP7450534B2 (en) 2017-10-19 2024-03-15 帝人ファーマ株式会社 Benzimidazole derivatives and their uses
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
KR20210059663A (en) * 2019-11-15 2021-05-25 가천대학교 산학협력단 Novel benzimidazole derivatives and its use
KR20210131855A (en) * 2020-04-23 2021-11-03 런엑스 주식회사 A pharmaceutical compositon for treating lung cancer comprising R-point regulatory protein complex as an active ingredient, a screening method for treating lung cancer using the formation of the complex, and a method for diagnosing lung cancer
WO2024023278A1 (en) 2022-07-29 2024-02-01 Ryvu Therapeutics S.A. Cancer combination therapy including a flt3-inhibitor
WO2024023279A1 (en) 2022-07-29 2024-02-01 Ryvu Therapeutics S.A. Cancer combination therapy including a bcl-2 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1122988A (en) * 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1469504A (en) * 1964-10-22 1967-02-17 Fisons Pest Control Ltd Insecticidal compounds
DE3227893A1 (en) * 1982-07-26 1984-01-26 Macherey-Nagel & Co Chemikalienhandel, 5160 Düren USE OF BENZIMIDAZOLE DERIVATIVES FOR DETECTING BLOOD AND OTHER PEROXIDATICALLY EFFECTIVE SUBSTANCES IN BODY LIQUIDS AND ELIMINATION PRODUCTS, IN PARTICULAR AS A DIAGNOSTIC IN THE FORM OF A TEST PAPER
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
WO1999016755A1 (en) * 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
NZ511825A (en) * 1998-11-27 2003-08-29 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
WO2006134318A1 (en) 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
CA2780031A1 (en) * 2009-11-12 2011-05-19 Selvita S.A. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
AU2013311826A1 (en) 2012-09-05 2015-03-26 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1122988A (en) * 1964-10-22 1968-08-07 Fisons Pest Control Ltd Benzimidazole derivatives
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491691A (en) * 2020-04-02 2021-10-12 深圳贝瑞生物医药科技有限公司 Compound for preparing antitumor drugs or 14-3-3 eta protein inhibitors
CN113491691B (en) * 2020-04-02 2023-04-14 深圳贝瑞生物医药科技有限公司 Compound for preparing antitumor drugs or 14-3-3 eta protein inhibitors
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CN104936951B (en) 2018-02-06
AU2013366513B2 (en) 2016-09-01
JP6169185B2 (en) 2017-07-26
IL239193A0 (en) 2015-07-30
PT2935244T (en) 2018-10-22
US10174013B2 (en) 2019-01-08
CY1120692T1 (en) 2019-12-11
EP2935244B1 (en) 2018-06-27
BR112015014701B8 (en) 2022-12-13
MX369589B (en) 2019-11-13
BR112015014701B1 (en) 2022-11-01
ES2688395T3 (en) 2018-11-02
KR20150095908A (en) 2015-08-21
PL2935244T3 (en) 2019-02-28
KR101779272B1 (en) 2017-09-18
US9388192B2 (en) 2016-07-12
US20150336967A1 (en) 2015-11-26
RS57658B1 (en) 2018-11-30
WO2014096388A3 (en) 2014-08-21
HUE039376T2 (en) 2018-12-28
JP2016503779A (en) 2016-02-08
BR112015014701A2 (en) 2017-07-11
US20170152249A1 (en) 2017-06-01
MX2015007057A (en) 2016-01-20
AU2013366513A1 (en) 2015-06-11
HRP20181429T8 (en) 2018-12-28
GB201223265D0 (en) 2013-02-06
SI2935244T1 (en) 2019-01-31
DK2935244T3 (en) 2018-09-10
HRP20181429T1 (en) 2018-11-30
LT2935244T (en) 2018-10-25
WO2014096388A2 (en) 2014-06-26
EP2935244A2 (en) 2015-10-28
CA2896156C (en) 2018-05-22
CA2896156A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CN104936951A (en) Novel benzimidazole derivatives as kinase inhibitors
RU2636589C2 (en) Aminopyrimidine kinase inhibitors
EP3438094A1 (en) Selective c-kit kinase inhibitor
EP2499117B1 (en) A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
CA3158951A1 (en) 4-substituted aminoisoquinoline derivatives
ES2930106T3 (en) Pyrrole-pyridine derivative compound, process for preparing the same, and pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases
JP5117374B2 (en) Heteroaryl urea derivatives useful for CHK1 inhibition
WO2003026666A1 (en) 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
TW200829583A (en) Anilinopiperazine derivatives and methods of use thereof
CN101472920A (en) Selective inhibitors of ROCK protein kinase and uses thereof
JP2016507509A (en) Azaindole derivatives as inhibitors of protein kinases
TW200524911A (en) N-substituted pyrazolyl-amidyl-benzimidazolyl C-KIT inhibitors
JP2009520791A (en) Enzyme inhibitor
JP2008535830A5 (en)
Wang et al. Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors
Li et al. Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer
WO2019038683A1 (en) Compounds targeting tandem brct domains of brca1, compositions and methods thereof
KR101118842B1 (en) 5-1,3-diaryl-1H-pyrazol-4-ylmethylene-thiazolidine-2,4-dione derivatives useful as antitumor agent
US20220274997A1 (en) Pim kinase inhibitor compositions and uses thereof
CN114206868A (en) 3- (2- (heteroaryl) -pyridin-4-yl) -5- (trifluoromethyl) -1,2, 4-oxadiazole derivatives as HDAC6 inhibitors
KR101118827B1 (en) 5-3-Aryl-1-phenyl-1H-pyrazol-4-ylmethylene-3-alkylcarboxy- rhodanine derivatives useful as antitumor agents
CN111138426B (en) Indazole kinase inhibitor and application thereof
KR101118768B1 (en) 5-3-Aryl-1-pyridyl-1H-pyrazol-4-ylmethylene-thiazolidine-2,4-dione derivatives useful as antitumor agent
TWI725041B (en) Chk1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas
EP2366695A1 (en) A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20150923

Assignee: Berlin chemistry limited-liability company

Assignor: Selvita Sp. Z. O. O.

Contract record no.: 2017990000476

Denomination of invention: Benzimidazole derivatives as kinase inhibitors

License type: Exclusive License

Record date: 20171204

GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Krakow

Patentee after: Ruiwu treatment Co.,Ltd.

Address before: Krakow

Patentee before: SELVITA S.A.